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STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS 
 
Michael McCarthy, M.S. 
 
Advisory Professor: Alemayehu A. Gorfe, Ph.D 
RAS, one of the most well characterized membrane-associated small GTPases, is a 
notorious oncogene with >15% of all tumors harboring RAS mutations. When RAS is 
mutated it becomes constitutively active sending cell growth, survival and proliferation 
into overdrive, which subsequently leads to cancer. Although, RAS has been 
aggressively targeted with drug design efforts for more than 30 years an FDA approved 
direct inhibitor has not yet been developed. There are three isoforms of RAS in cells; 
HRAS, NRAS and KRAS. We focused on KRAS since it is the most frequently mutated 
isoform in cancer.  To identify novel non-covalent small molecules that bind to mutant 
KRAS, we conducted a high-throughput virtual screen of drug-like compounds against a 
previously characterized allosteric pocket on a molecular dynamics simulation-derived 
KRASG12D structure. The in silico predicted hits were then validated with a battery of cell-
based and biophysical assays. Specifically, the hits effects on KRAS signaling, binding 
affinities for KRAS and mechanisms of activity were evaluated. We found two key hit 
compounds (i) a pyrazolopyrimidine based molecule compound 11 and (ii) a indazole 
based molecule compound M1.  Compound 11 exhibited a monotonous dose-dependent 
inhibition of KRAS signaling, however compound M1 demonstrated a biphasic dose-
depended effect.  With the potential to elucidate the structure-activity relationships 
between these molecules and their unique structures we tested both in cell-based and 
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biophysical assays.  We found that compound 11 binds to KRAS with nanomolar affinity 
and completely abolishes CRaf binding in vitro, subsequently leading to a significant 
reduction in RAS dependent CRaf/ERK activation and son of sevenless (SOS) mediated 
nucleotide exchange.  Moreover, treatment at low micromolar concentrations of 
compound 11 reduced cell proliferation in six cancer cell lines.  
Further, compound M1, binds to KRAS in NMR-based studies and both reduced and 
enhanced signaling in cell-based assays as indicated by western blotting. We attributed 
this to M1 enhancing and disrupting nucleotide exchange through different mechanisms.  
Additionally, we noted that M1 showed remarkable selectivity towards inhibiting 
proliferation of MiaPaCa-2 cells.  
We then screened a second small-molecule library based on M1 and generated 
additional hits which decreased mutant KRAS signaling.  Likewise, we generated two 
derivatives of compound 11 which were tested and gave insights to critical functional 
groups.  Combining our results with detailed structural analysis, we are able to describe 
key ligand-receptor interactions that correlate with activity. Thus, showing that our 
screening techniques were very successful at generating KRAS binders that have effects 
on signaling in cells. 
To our knowledge compound 11 is the first known nanomolar binder of KRAS that 
disrupts interaction with CRaf resulting in decreased p-ERK levels and cell proliferation. 
Therefore, compound 11 is a promising hit for the development of novel non-covalent 
KRAS inhibitors.  
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Chapter 1: Introduction 
Portions of this chapter are reproduced with permission from the review article 
McCarthy M., Prakash P., Gorfe A. A., 2016 Computational allosteric ligand binding site 
identification on Ras proteins. Acta Biochimica et Biophysica Sinica. 
 
 
1.1 Cancer and RAt Sarcoma (RAS) 
 Cancer has a major impact on public health with over 15 million Americans living 
with some form of the disease in 2016 and about 1,700,000 new cases of cancer 
diagnosed in 2017 [1]. Broadly, cancer is defined as unrestrained cell growth that 
becomes invasive to the organ of origin and eventually spreads to other tissues. 
Specifically, there are 10 hallmarks of cancer; evading the immune system, enhancing 
inflammation (promotes tumor growth), metastasis (spreading), angiogenesis 
(generating blood supply), suppressing growth restriction, genome instability, immortality 
(activated telomerase), altered cell metabolism, insensitivity to death signaling and 
enhanced proliferative and survival signaling [2]. Molecularly, cancer can be driven by 
the alteration of a single gene. Genes with the potential to cause cancer when mutated 
are referred to as oncogenes. The first oncogene was discovered in 1970 in a chicken 
virus, later termed src, and fundamentally changed our understanding of the molecular 
biology of cancers [3]. Then came the discovery of other major oncogenes that drive 
cancer. In 1982 the RAS family of genes, which were originally discovered in a virus in 
rats in the 1960s, was identified in human cancer cells by their ability to transform mouse 
fibroblasts [4; 5]. Since their discovery, the RAS family of genes has been one of the 
most widely studied genes for their role as a driver of cancer in a variety of different types 
of tumors [6].  
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1.1.1  RAS proteins overview 
RAS is a membrane-anchored 21 kDa guanosine triphosphate (GTP) binding 
protein, which transduces extracellular signals from trans-membrane receptors, such as 
the epidermal growth factor receptor (EGFR), to numerous downstream effectors thereby 
activating cell growth, survival and proliferation. RAS is oncogenic when mutations 
render it constitutively active [6-8]. There are three major RAS proteins in humans: N-, 
H- and KRAS and all share essentially the same catalytic machinery, but a divergent C-
terminal hyper variable region (HVR). RAS is a globular protein with a catalytic domain 
that consists of 5 α-helices, a 6 strand β-sheet and 10 loops.  The HVR of KRAS contains 
a polybasic stretch of 6 lysines, and is post-translationally modified at a putative CAAX 
box to attach a farnesyl group. Both the polybasic domain and the farnesylated domain 
play a critical role in anchoring and localization of KRAS to the cytosolic side of the 
plasma membrane [9-11]. Once localized, KRAS functions as a switch cycling between 
two states; GTP-active and GDP-inactive [12]. When GTP bound, KRAS exists in two 
conformational states either an active state with high affinity for effectors or an inactive 
state with low affinity for effectors. GTPase Activating Proteins (GAP) facilitate the 
hydrolysis of GTP to GDP, which stops KRAS signaling [13]. Guanine nucleotide 
Exchange Factors (GEF) such as son of sevenless (SOS) catalyzes nucleotide exchange 
by causing conformational changes in the switches that allows GDP to dissociate from 
RAS, so that another GTP molecule can bind [14]. When active, KRAS binds to effectors 
and triggers the auto-phosphorylation of effectors, such as 
Rapidly Accelerated Fibrosarcoma (CRaf) in the mitogen-activated protein kinase 
(MAPK)-extracellular signal-regulated kinase (ERK) pathway or phosphatidylinositol-4,5-
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bisphosphate 3-kinase (PI3K) in the PI3K/AKT (protein kinase B) pathway, activating 
them [15-17]. Therefore, Ras plays an integral role in many cellular processes that range 
from development and differentiation to calcium regulation and apoptosis [11; 18].   
 
1.1.2 RAS isoforms in cancer 
Activating somatic mutations in RAS proteins occur in >15% of all human tumors 
[19]. However, the three RAS isoforms also differ in their ability to drive cancer formation 
[20]. KRAS mutations represent ~84% of all oncogenic RAS mutations and are frequently 
found in lung, colorectal, and pancreatic carcinomas [21-24]. NRAS mutations are 
common in melanomas, hepatocellular carcinomas, and hematologic malignancies [25-
27]. Although less frequent, HRAS mutations are found in bladder, kidney, and thyroid 
carcinomas [19; 28; 29]. Frequently mutated residues of RAS are G12 and G13 in the 
phosphate binding loop (p-loop). Mutations at these positions in the p-loop inhibit the 
function of GTPase-activating proteins (GAPs), such as p120 GAP [30]. Common 
examples include G to D, G to V or G to A mutations, which block R789 of GAP proteins 
from being inserted into the nucleotide binding pocket, a requirement of GAP catalyzed 
GTP hydrolysis [31; 32]. Another common site for activating mutations is amino acid Q61, 
which also inhibits GAP activity [32]. In either case RAS becomes constitutively active 
and drives cell signaling, subsequently resulting in cancer. Therefore, RAS proteins 
remain one of the most crucial anti-cancer drug targets [33].  
 
1.1.3: Towards inhibiting KRAS signaling 
Over the years, a number of different approaches have been used to inhibit KRAS. 
These include indirectly perturbing membrane binding of KRAS, thereby blocking the 
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activity of KRAS, and inhibiting downstream effectors directly [34-37]. Examples of the 
former include development of farnesyltransferase inhibitors (FTIs) [38-41] and farnesyl 
analogues [42-44], compounds that modulate plasma membrane lipid distribution [45-
47], as well as inhibition of trafficking proteins responsible for localizing KRAS on 
membranes, such as PDEδ [48; 49]. The goal is to disrupt KRAS membrane binding, 
which is required for its biological activity. While the impact of the latter three classes of 
compounds is yet to be determined, FTIs turned out to be a major disappointment [50]. 
This is because KRAS and NRAS can be alternately prenylated by geranyl-geranyl 
transferase, thus bypassing FTI treatment [51], and combination therapy with multiple 
prenylation inhibitors led to severe toxicity [40]. Some success has been achieved in 
inhibiting BRaf, a downstream effector of RAS, with sorafenib, vemurafenib [52] and 
dabrafenib [53], and MEK with trametinib, which treats some forms of melanoma and 
renal cancer [54].  However, in some studies inhibition of BRaf has also led to a 
paradoxical activation of the RAS signaling pathway by enhancing heterodimerization 
between CRaf and BRaf at therapeutically relevant concentrations. However, efforts are 
still ongoing to inhibit other MEK and ERK related pathways [55].  
 
1.1.4: KRAS as a druggable target  
Studies have shown that inhibition of KRAS signaling can cause mutant KRAS 
dependent tumors to shrink, making it an attractive drug target [56].  The nucleotide-
binding site would have been a logical target for structure-based ligand design for KRAS. 
However, that ligand binding pocket is conserved in other families of GTPases and 
therefore targeting that site would likely lead to problems of selectivity and toxicity. 
Although there are ongoing efforts toward developing GDP analogues for covalent 
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binding to KRASG12C [57; 58], such an inhibitor would not be applicable to the majority of 
oncogenic KRAS mutations since the other mutated residues cannot covalently bind 
small molecules [59]. Even if selective inhibitors of the active site were identified, the 
high intracellular concentrations of GTP and GDP and their high (picomolar) affinity for 
KRAS would make competitive inhibition impractical [31]. Further, it is apparent in many 
crystal structures that KRAS has a surface that is relatively smooth and without obvious 
allosteric pockets to target, thus it has proven to be a challenging target.  Alternative 
strategies are needed to target abnormal RAS function.  
 
1.2 Discovery and validation of four allosteric binding sites on RAS 
In the recent past our group [60-63] as well as others [64-70] demonstrated that 
RAS is an allosteric enzyme with multiple surface pockets, which opened up a promising 
new direction towards inhibiting RAS directly (see [71; 72] for recent reviews). These 
discoveries were significantly facilitated by computational methods [60; 61], which 
provided the initial clues into the potential “druggability” of RAS [20].  This conceptual 
advance led to the prediction of four allosteric ligand binding sites based on different 
computational approaches, primarily ensemble-based blind docking and FTMap [70; 73]. 
The ensemble-based approach accounts for RAS flexibility and conformational 
transitions using molecular dynamics (MD) sampling of configurational space, followed 
by blind docking of drug-like molecules on the entire surface of each receptor 
conformation to search for allosteric binding sites. FTMap uses a continuum approach 
for docking of molecular fragments on the surface of a rigid receptor [74].  
The four allosteric ligand binding sites predicted by these methods were 
subsequently confirmed by NMR or X-ray crystal structures of RAS in complex with 
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small-molecule ligands [64; 67; 75-78]. These ligands either interfere with GDP-GTP 
exchange [64; 68; 69], stabilize the inactive GTP-bound conformation of RAS (state 1) 
[66; 67] or prevent RAS-effector interaction [68] (Figure 1.1) [79-81]. While many small 
molecules that bind KRAS have been identified, so far none have been FDA approved. 
Table 1.1 and Figure 1.2 summarize the location of these pockets and the ligands that 
have been determined or predicted to bind to them. Because all of these sites have been 
discussed in detail in previous reports [64; 67; 75-78], I provided only a brief summary of 
their key features that will facilitate future drug design. It is important to note here that 
most of these ligands were discovered through in silico screening of ligand libraries [68] 
or via nuclear magnetic resonance spectroscopy (NMR)-based screening of molecular 
fragments [64; 66; 67]. 
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Figure 1.1: Modulation of the GTPase cycle and effector interaction of RAS by weak 
allosteric inhibitors that have been discovered in the past several years.  The catalytic cycle 
of RAS (left) and the two substates of GTP-bound RAS (right) are highlighted in cartoon diagram. 
The inverted T sign indicates the site of action of different ligands. GEF, guanine nucleotide 
exchange factor; GAP, G-protein activating protein. 
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Three of the four pockets (p1, p2, and p4) are located near the functionally critical 
switch regions. Since the switch regions interact with RAS activators and effectors, 
ligands that target any of these pockets can be expected to directly or allosterically 
modulate binding to proteins either upstream or downstream of RAS. This is indeed the 
case [64; 67; 75-77; 82]. As indicated in Table 1, residues on switch 2 and the β1–3 
strands were shown to be involved in stabilizing ligands bound to p1 [64; 75; 77], and p1 
is the target site for the majority of NMR and X-ray structures of RAS-ligand complexes 
solved to date. These include 4,6-dichloro-2-methyl-3-aminoethyl-indole (DCAI) [64], the 
Kobe-family ligands [75], and other ligands with specific chemotypes including indoles, 
phenols, sulfonamides, and their analogs [77]. Crystal structures of ligands bound to p2 
(broadly defined) that form a covalent bond to the Cys of a G12C mutant RAS have been 
solved recently [78]. These ligands span either of two subpockets lying toward switch 2 
or α-helix 3. Evidence from NMR and MD studies suggest that p4 is a viable drug target 
in RAS structures with open switch 1 conformation [67; 82]. Finally, pocket p3, which has 
been shown to be targeted by metal-cyclens, is unique in terms of its distant location 
from the active site as it lies near the C-terminal end of the protein [67; 76]. Therefore, it 
is likely to be more significantly affected by membrane binding. 
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Table 1.1: Binding sites/pockets of RAS characterized by experimental and 
computational studies. 
Binding site  Region  Ligand  
p1  β1–3, switch 2  
DCAI [42], Kobe ligands [46], indole, phenol, 
sulfonamide-containing ligands [47]  
p2  
Loop2, switch 2, 
and helix 3  
Compounds specific for G12C Ras [43]  
p3  Loop7 and helix 5  M2+-BPA [45], M2+-cyclen [44]  
p4  switch 1  
M2+-BPA [45], Andrographolide derivatives 
[39]  
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Figure 1.2: The location of allosteric ligand binding sites on RAS. Four ligand binding sites 
are shown in different colors and labeled as p1 (light blue), p2 (green), p3 (yellow), and p4 (pink). 
The residues that define these pockets are listed in [83]. Note that in this illustration I used a 
single structure of KRASG12D in which some of the pockets are not fully open. As discussed in the 
main text, opening of some pockets in RAS requires relaxing the protein through MD simulation.  
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1.3 Computational approaches to target RAS 
Given the involvement of mutant RAS in almost every cancer type, the need for 
discovering drugs that inhibit activated RAS signaling cannot be overstated. Drug 
discovery, however, is a very complex and expensive process that takes years and costs 
billions of dollars [84]. Structure-based computer aided drug design (CADD) approaches 
can expedite the process and reduce cost [85]. As a result, high throughput virtual 
screening (HTVS) of ligand libraries has become an integral part of drug design programs 
in both industry and academic laboratories [86; 87]. A major focus of this thesis is the 
high throughput virtual screen we conducted to search for  direct inhibitors of KRAS. In 
this section I begin with a general overview of structure-based computer aided drug 
discovery. I then discuss the four allosteric ligand binding sites obtained from 
computational and experimental studies, followed by rigorus biophysical and in vitro 
characterization of hits obtain in the HTVS.   
 
1.3.1: Structure-based computer aided drug design (CADD) 
The CADD workflow used for this thesis is shown below in Figure 1.3. One of the 
key starting points for CADD is a well-characterized target whose atomic structure has 
been determined to a sufficiently high resolution [88]. KRAS meets this condition with 
more than 70 high resolution crystal structures available in the protein data bank. Also of 
key importance is knowledge about the potential drug binding site or pocket(s) on the 
surface of the target [89; 90]. In most cases, the target site for docking is the functionally 
most responsive orthosteric site, which, for example, can be the active site of an enzyme 
[91] or the agonist/antagonist-binding site of a G-protein coupled receptor. In some 
cases, active site inhibition is either ineffective or leads to toxicity if the site is highly 
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conserved among related proteins. For such targets allosteric inhibition is the preferred 
(or only) option to achieve enhanced selectivity or reduced toxicity. Moreover, some of 
the most effective drugs on the market are allosteric inhibitors (e.g., Gleevec [92]). The 
first crucial step for a successful structure-based discovery of an allosteric inhibitor is 
identification of an allosteric ligand-binding site [93].  
 
1.3.2: High-throughput virtual screening  
After target selection and binding site identification, one can conduct HTVS of 
ligand libraries against the target site. There are a number of knowledge-based and/or 
physics-based algorithms to perform HTVS using various energy functions for docking 
and scoring. Many excellent reviews have discussed current HTVS techniques as well 
as their advantages, limitations and potential for improvements [85; 87; 94; 95]. In short, 
HTVS requires careful selection of small molecule ligand libraries [96], which involves 
among other things setting up criteria for molecular size, solubility and cell permeability 
[97-99]. There is a wealth of data on small molecule ligands in public databases such as 
ZINC [100] and PubChem [101]. These depositories of large numbers of drug-like small 
molecules provide ready-to-use, downloadable files of ligand libraries [87; 101].  A 
focused library biased toward a given set of compounds can also be generated based 
on known high affinity binders via similarity searches and knowledge-based culling [87].  
Once the desired ligand library is chosen, HTVS can be conducted using a number of 
programs such as GLIDE, DOCK and AutoDock4 [102-112] (Figure 1.3).  The output of 
these algorithms includes docking scores (typically based on an estimate of the binding 
free energy) and the structure of the predicted target-ligand complex. The final result is 
a list of predicted hits ranked by binding free energy score, ligand pose, or both. It is 
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often useful to obtain a consensus score from multiple docking runs and different 
programs to reduce false positives that usually arise from limitations in the scoring 
functions [113; 114]. The predicted hits can then be validated by experimental methods. 
If desired, promising hits can then be subjected to a series of optimization steps to 
generate a lead compound with the desired potency and selectivity (Figure 1.3).  
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Figure 1.3: Overview of computer-aided drug design strategy used for this thesis.  Shown 
here is a simplified workflow of a structure-based computer-aided drug design process involving 
target selection, binding site identification, high-throughput virtual screening of ligand libraries, 
experimental validation, and optimization for potency and selectivity.  
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1.3.3 After the screen; experimentally validating hits.  
Validating hits generated by the HTVS is not an easy task but there are many biological, 
biochemical and biophysical approaches.  Biophysical approaches when considering 
targets like KRAS can include microscale thermophoresis (MST), isothermal calorimetry 
(ITC), nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), X-ray 
crystallography, nucleotide exchange assays, fluorescence polarization assays and 
fluoresence lifetime imaging (FLIM) combined with Forester resonance energy transfer 
(FRET), among many other techniques.  For MST, ITC, NMR and SPR, binding can be 
monitored in real time by detecting changes in the target state following small molecule 
addition to the solution such as diffusion in MST or resonance shifts in SPR. The data is 
analyzed to confirm the significance of the changes and binding affinity can be calculated 
for MST, ITC and SPR. The advantage of these techniques is their simplicity, typically 
the protein and the molecule being tested are the only two components causing a 
change, thus simplifying data interpretation. For X-ray crystallography the protein is 
crystalized with or without the compound.  If the protein will not crystalize with the 
compound, the crystal can be soaked in a solution with the compound, which could allow 
for binding.  After the crystal is subject to intense X-rays, detailed structural information 
of the protein and ligand complex can be obtained by analyzing the X-ray scattering data.  
Fluorescence based assays such as nucleotide exchange or fluorescence polarization 
can involve endogenous ligands that are modified to fluoresce. Typically, these assays 
monitor a change in fluorescence which is attributed to the molecule disrupting protein-
protein interactions or protein-ligand binding.  Although these assays can be ambiguous 
by indicating multiple targets for binding, they usually require less expensive equipment 
and are less difficult to conduct compared to crystallography. The advantage of FLIM-
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FRET assay is that they assess binding and disruption of protein-protein interactions in 
the native cellular environment. With KRAS and RAF as an example, a donor fluorophore 
can be attached to KRAS and an acceptor to RAF, such as GFP and RFP respectively.  
When KRAS and RAF interact the fluorescence emission lifetime of GFP will change.  If 
the molecule disrupts that interaction that too will have an effect on the emission lifetime 
of GFP [115].    
For biochemical experiments, alteration of the signal transduction pathway can be 
assessed.  For KRAS disruption of effector binding can be measured by quantitative 
western blotting using antibodies to the activated downstream proteins, i.e. phospho-
ERK and phospho-AKT.  
Disruption or enhancement of protein-protein interactions can be assessed with 
pulldown assays. For example, I measured KRAS precipitation by a Glutathione S-
Transferase (GST) fusion construct of the Ras Binding Domain (RBD) of RAF. Hit 
molecules can be tested in these assays to determine if the compounds will interfere with 
protein-protein interaction.  
Alternatively, disruption of signaling for KRAS can be evaluated by enzyme-linked 
immunosorbent assays (ELISA). Such assays offer high throughput detection of total and 
phosphorylated ERK levels using common 96-well plate setup and readers.  Other similar 
calorimetry assays such as MTT (detects cell metabolism) and the CyQuant cell 
proliferation assay (detects DNA content) can indicated changes to cell proliferation due 
to treatment with hit compounds.  Finally, xenograft animal models can be used to test 
absorption, distribution, metabolism, excretion, and toxicity (ADMET) as well as effect of 
hit molecules on tumors in live animals.  These are a few of the many techniques and 
assays available to thoroughly validate the hits generated in silico.   
17 
 
 
1.3.4: Summary of goals of this study 
In summary, unregulated signaling from mutant KRAS can drive cancer tumor 
formation; therefore, abrogating constitutively active KRAS signaling could have a 
significant impact in many types of cancer. Previously, KRAS was considered an 
“undruggable” target and to-date the FDA has not approved any compounds to target 
KRAS in cancer.   Thus, the goal of my thesis work was to identify “drug-like” small 
molecules that abrogate oncogenic KRASG12D signaling [5].  To accomplish this, we 
combined an HTVS, biophysical assays and cell-based assays.  First, ligand libraries 
containing millions of compounds were screened in silico against a carefully selected MD 
derived KRASG12D conformation to identify potential hits.  Next, cell-based assays were 
used to determine the effect of the ligands on KRASG12D signaling.  Finally, biophysical 
assays such as microscale thermophoresis (MST), nuclear magnetic resonance (NMR) 
and fluorescence polarization were utilized to evaluate effects of binding to KRAS and 
determine affinity of the molecules for KRAS.  
We found five molecules that bind to KRAS and alter its interaction with effector 
proteins to change signaling output.  Of particular interest is a pyrazolopyrimidine based 
molecule, compound 11, which bound to KRAS with nanomolar affinity and completely 
abolished CRAF binding in vitro, subsequently leading to a significant reduction in RAS 
dependent CRAF/ERK activation and both intrinsic and SOS-mediated nucleotide 
exchange.  Moreover, treatment at low micromolar concentrations of compound 11 
reduced cell proliferation in five cancer cell lines. This work has laid a strong foundation 
for developing a therapeutic RAS inhibitor. 
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Chapter 2: Materials and Methods 
 
2.1 High throughput virtual screen 
 The core of this project is a high throughput virtual screen of drug-like molecules 
through an experimentally validate allosteric pocket on KRAS.  We started with molecular 
dynamics simulations to generate pocket conformations that were not available in KRAS 
crystal structures.  This allowed us to search a wider range of molecules in terms of size 
and combinations of chemical group moieties. Therefore, this project had the potential to 
identify drug-like small molecules that had new features and more potential as viable 
leads.  
 
2.1.1 Molecular dynamics simulation  
Oncogenic KRAS mutants are constitutively active because their ability to 
hydrolyze GTP is compromised [116; 117]. An inhibitor that selectively targets GTP-
bound mutant KRAS would therefore be desirable. However, there was no high-
resolution experimental structure of GTP-bound KRAS (GTPKRAS) when we started this 
project, and our target pocket p1 (Figure 1.2) was closed in the available GDP-bound 
KRAS (GDPKRAS) structures. Therefore, we used molecular dynamics (MD) simulation 
to generate an ensemble of GTPKRAS structures. The initial structure for the simulation 
was a GDP-bound KRASG12D X-ray structure from the PDB (ID 4DSO) [118]. Before 
initiating the simulation, we made the following changes to prepared the system for 
KRASG12D: converted GDP to GTP, remove other molecules (i.e. benzamidine), except 
crystal waters, and added hydrogen atoms and solvent. After minimization and a 
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restrained simulation, we conducted a 300 ns production run using an identical protocol 
to that described in a recent report [119]. The trajectory was analyzed in terms of volume 
and other features of our target pocket p1 and the conformation with the most open p1 
was selected for virtual screening of ligand libraries. 
 
2.1.2 Docking 
For this project molecules from the ZINC database were used. ZINC is a free 
resource that contains over 30 million “drug-like” molecules most of which are 
commercially available.  The molecules in ZINC are downloadable in ready-to-dock 3D 
formats [120].  The philosophy behind the small molecules selected was that they fit 
Lipinski’s criteria, which is suggested to be optimal for ADMET [97].  The HTVS used the 
ligand library called “drugs_now” in the ZINC database, from which we docked over 6 
million commercially available compounds. With help from John Rogers, a summer 
student in our lab, all compounds were docked on an MD derived KRASG12D 
conformation.  We chose pocket 1 which is located between the central beta sheet and 
switch 2.  The residues that compose this pocket (residues 5-7, 37, 39, 50-56, 67 and 
70-75) are vital to KRAS effector function. Specifically, residues 37, 38, 39, 41, 54 are 
important for interactions with downstream effectors, such as RAF and PI3K, while 
residues 36, 37, 38, 67 and 70 are important for interactions with GEFs, such as SOS 
[121].  Therefore, a molecule that binds to this pocket could disrupt the ability of KRAS 
to interact with a putative GEF or some direct effectors.  
As a first run these compounds were docked by AutoDock4 v4.0.1 which was 
implement by DOVIS to run in parallel on our in-house cluster [122].  The AutoDock4 
parameters used were 1 million energy evaluations with 150 generations with Lamarkian 
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genetic algorithm option.  AutoDock Tools was used to add Gasteiger charges and 
assign atomic radii, and we docked with a flexible ligand but a rigid receptor and the gird 
spacing was set to 1 Å.  These parameters allow us to dock around 60,000 molecule a 
day on 10 nodes.  The molecules that scored over ΔG = -6.8 kcal/mol were re-screened 
with VINA [123].  Out of 6 million compounds 3,762 scored in that criteria or higher. For 
the VINA screen the exhaustiveness setting was 12 and an energy range setting was 4.  
I then quantified 8 ligand receptor interactions with a python script developed by Durant 
et al.  [124]. The script evaluates the following interaction with the corresponding 
parameters: 
Close contacts between ligand and receptor. Cutoff = 2.5Å 
Contacts between ligand and receptor. Cutoff = 4.0Å 
H-Bonds between ligand and receptor. Cutoff = 3.2 Å : Angle = 30.0 
Salt bridges between ligand and receptor. Cutoff = 5.5 Å  
Cation-pi interaction between ligand and receptor = 4.0 Å 
Pi-pi interaction between ligand and receptor pi-padding = 0.75 Å : Angle 
tolerance 30.0 
T-Stacking interaction between ligand and receptor.  Closest dist cutoff = 5.0 Å : 
Angle = 30.0 
Hydrophobic interactions between ligand and receptor. Dist-cutoff = 4.0 Å 
 
2.2 Cell-based screen 
 At the start of this project we did not have a cell model that contained KRASG12D.  
However, Dr. Cho in the Hancock lab at the time, had previously established a GFP-
KRASG12V-expressing baby hamster kidney (BHK) cell-line.  Using a standard PCR-
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based mutagenesis protocol, we changed the 12V to 12D and then confirmed the 
mutation by sequencing.  We used the new construct to establish a KRASG12D-
expressing BHK cell line.  
 
2.2.1 BHK cell line general transfection protocol 
BHK cells were transfected with PEF6 plasmids containing GFP-KRASG12D.  
2.0x105 BHK cells were seeded onto a 6-well plate. In tubes 160 L OptiMEM + 1 g 
mGFP-KRASG12D were mixed and then 163 L of OptiMEM + Lipofectamine at a ratio of 
1 : 20 was added. The tubes were then incubated for 20 min at room temperature. After 
washing the cells with PBS x 1 and OptiMEM x 1,1.28 ml of OptiMEM was applied to 
each well. Following incubation, the contents of each tube was applied to each well one 
drop at a time and then the plate was gently rocked to mix. The media was changed after 
a ~3 h incubation. The cells were then incubated at 37 oC and checked the next day.  
 
2.2.2 Generating monoclonal cell line 
Stably transfected polyclonal BHK cells were trypsinized (trypsin 0.05 %) for 2 
min, separated by pipetting 20 x, washed by centrifuging for 5 min at 1,000 rpm, 
aspirating the old media and then resuspended in fresh media.  The cells were then 
counted with trypan blue and the Countess cell counter (InvitrogenTM).  The cells were 
then diluted to a concentration of 1 cell per 100 l and plated in 96 well plates with 100 
l of cell suspension per well.   This resulted in approximately 1 cell per well and 4 plates 
were setup similarly.  As the cells grew they were monitored visually with microscopy.  
Any wells with more than one colony were marked and discarded.  The cells that 
contained only one colony were selected with a maximum of 5 wells per plate. When 
22 
 
cells reached confluency, the colonies transferred to larger wells for expansion. Colonies 
that displayed obvious changes in morphology or loss of GFP were discarded.  Once the 
cells expanded to a T75 flask they were checked with confocal microscopy to assess 
morphology and GFP expression level.  The cells were ranked qualitatively and the best 
colonies were expanded to save stocks for future experiments.  
 
2.2.3 Making cell aliquots or cell stocks 
The freezing media contained 10 % FBS and 10 % DMSO v/v in Dulbecco's 
Modified Eagle Medium (DMEM, HycloneTM). The media was filtered with a 0.2 micron 
filter to ensure sterility. The cells were then trypsinized with 2 ml of trypsin for 2 min and 
then 2 ml of fresh normal media was and cells were separated as described previously. 
The cells were centrifuged at 1,000 rpm for 5 min at room temperature to pellet and the 
media was carefully aspirated. Finally, the cells were resuspended in freezing media, 
~15 ml. The cells were vortexed briefly to mix and 1 ml was aliquoted to each cryo-tube.  
The cells were frozen at -80 °C overnight and then transferred to liquid nitrogen for long 
term preservation.  
 
2.3 Westerns 
  Two different methods were used to prepare samples for western blotting.  During 
the initial compound screen, a quick method was used that did not involve measuring 
protein concentrations.  After treatment with compound, cells were harvested in lysis 
buffer, containing 50 mM Tris-HCL, pH 7.5, 5 mM MgCl2, 25 mM NaF, EGTA, 1% Nonidet 
P40 and Leuceptin, NaVO4, DTT and Aprotinin. To harvest cells, the media was 
aspirated and cells were washed with cold 1 x PBS three times. Lysis buffer was added 
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and cells were scraped off the plate. Before scraping a new well, the scrapper was 
washed with Milli-Q purified water. While keeping everything on ice the lysis buffer - cell 
suspension was transferred to an Eppendorf tube. To lyse the cells, the tubes were twice 
vortexed for 10 sec with 5 min rest on ice in between vortexing.  To collect the cell lysate, 
the tubes were centrifuged in the cold room for 5 min at max speed (~14,000 rpm). The 
supernatant was transferred to a new tube and the cell pellet was discarded.  
To prepare western samples, during the cell-based screen, 3 µl of 5 x sample 
buffer was added to 10 µl of each sample of cell lysate for a total of 13 µl.  Each sample 
was mixed and then centrifuged at max speed for 3 sec.  The samples were heat 
denatured for 5 mins at 95 °C.  Then samples were resolved with a precast Bio-Rad 
polyacrylamide 10 % Tris-HCl gel at 80 mV for approximately 2 h and then transferred to 
a polyvinylidene fluoride (PVDF) membrane.  
To prepare the membranes for transfer, the first step is to hydrate them by briefly 
soaking in methanol (~10 sec) and then they are transferred to 1 x transfer buffer to 
incubate under constant agitation until needed. Once the gel is out of the apparatus, it 
can be cut if needed (to use one gel with two different antibodies for detection). It is then 
washed with 1 x transfer buffer before placing it on the membrane. To prepare the gel 
for transfer a cassette of membrane, gel and filter paper is made in the following order 
from the anode up: filter paper, hydrated membrane, gel, filter paper and then cathode. 
Finally, the Bio-Rad semi-dry transfer system would run at 15 mV for 30 min per gel.  
After the transfer was complete, the membrane was transferred to 6 ml of blocking 
solution which was either 5 % BSA or Milk and incubated under constant agitation for 1 
h. After blocking, the membranes were incubated with primary antibody overnight at 4°C, 
again with agitation.  Membranes were then washed in 1 x TBST, for 5 min in triplicate 
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and then the secondary antibody solution was added for a minimum 1 h incubation at 
room temperature.  
For developing the membranes, enhanced chemiluminescence (ECL) was used. 
1.6 ml of component 1 and the same volume of component 2 was added to the 
membrane. If needed, equal volumes (100 – 400 μl) of Dura ECL enhancer was also 
added. The solutions and membrane are then mixed and incubated under constant 
rocking for 5 minutes before imaging the membrane. Images were taken on the Bio-Rad 
Gel-DocTM XR+ system. After developing the membranes, equal loading of protein was 
checked by staining with Coomassie Blue.  However, in later experiment either actin, 
GST or GFP was used as a loading control.  
After the initial screen, a standard BCA protein assay was used to determine the 
protein concentration of each sample before running the western. The protein assay for 
each sample and standard curve was prepared and analyzed using standard protocols. 
For subsequent western blots preparations of ~15 µg of protein (adjusted depending on 
total protein recovery), 5 x sample buffer, and H20 for a final volume of 20 μl per well, 
were produced.  
For immunoblots I used the following antibodies pan-AKT (2920S), GFP (2956S), 
pAKTS473 (4060L), p-cRafS338 (9427S), p-ERKT202/Y204 (4370L), ERK1/2 (4695S) or β-
actin antibodies (Cell Signaling Technology). The IC50 values calculated from dose-
response data described in the text were calculated with Prism 4-parameter fit.  
 
2.4 FRET experiments 
To determine if compounds disrupt the interaction between KRASG12D and CRaf 
we conducted FLIM-FRET experiments with FRET pairs GFP-KRASG12D and RFP-CRaf.  
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The cells plated on coverslips were transfected with GFP-KRASG12D and full-length RFP-
CRAFWT then treated with indicated concentrations of compound for indicated incubation 
durations in serum free media. Then the cells were fixed and imaged with the Lambert 
FLIM-FRET microscope. To fix cells for FRET the following reagents were gathered: cold 
1 x PBS, and paraformaldehyde (PFA) (made from 16 % PFA stock that was diluted 1 : 
4 with 1X PBS).  
To fix the cells, first they were washed twice with cold PBS (2 ml per well for 6 
well plate, 1 ml for 12 well plate). Then ~1.2 ml of 4% PFA was added and incubated for 
30 min in the dark. The PFA was collected and cell were washed 2 ml PBS twice. Next, 
the cells were incubated for 10 min with ~1.2 ml of 50 mM ammonium chloride (NH4Cl). 
The NH4Cl will quench the autofluorescence of the PFA.  
To mount the coverslips on glass slides, coverslips were first dipped with gentle 
agitation in a 100 ml beaker of PBS and then another beaker with Milli-Q water. To 
remove excess water the coverslip edges were dried with a paper towel. The coverslip 
was placed cell side down lowered into mounting media on the glass slide , while 
avoiding bubbles.  
FLIM-FRET experiments were carried out using a lifetime fluorescence imaging 
attachment (Lambert Instruments, The Netherlands) on an inverted microscope [115]. 
BHK cells transiently expressing mGFP-tagged KRASG12D (donor), alone or with mRFP-
tagged cRafWT (acceptor) (using 1:5 ratio), were prepared as indicated in each 
experiment. The samples were excited using a sinusoidally modulated 3 W 470 nm light-
emitting diode at 40 MHz under epi-illumination. Fluorescein was used as a lifetime 
reference standard. Cells were imaged with a Plan Apo 60X 1.40 oil objective using an 
appropriate GFP filter set. The phase and modulation were determined from 12 phase 
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settings using the manufacturer’s software. Resolution of two lifetimes in the frequency 
domain was performed using a graphical method [125] mathematically identical to global 
analysis algorithms [126; 127]. The analysis yields the mGFP lifetime of free mGFP 
donor (1), and the mGFP lifetime in donor/acceptor complexes (2). FLIM data were 
averaged on a per-cell basis.  
 
2.5 Protein purification for pulldown  
First, a plate was streaked with E. coli BL-21 bacteria, containing a previously 
generated pGEX plasmid with GST-CRaf-RBDA85K (from hereon GST-RBD), from a 
freezer stock and incubated overnight. Then, a single colony was picked from the plate 
to inoculate 4 ml of media that contained antibiotic. After overnight growth 3 ml of the 
culture was used to inoculate 100 ml of warmed fresh media with antibiotic. The density 
of the cell culture was monitored until it reached an OD at 600 nm of 0.5 – 1. Then IPTG 
at 1 : 1000 was added to the culture and the cells were grown  for an additional 4 h. After 
4 h 1ml of culture was saved as a sample to measure by western the protein expression 
after induction. The remaining culture was pelleted by centrifuging at 6,000 g for 5 min, 
at 4 ºC. To lyse the cells, the pellet was re-suspended in lysis buffer (1 x PBS, 5 mM 
EGTA, 1 % Triton X, PIC 1 : 50, PMSF 1 : 100) and then frozen. Two additional freeze-
thaw cycles were performed to lyse the cells. The cell lysate was then sonicated as 
needed and spun at 30,000 g for 20 min at 4 oC. Finally, the supernatant was combined 
with 400 µl of beads/buffer slurry (the buffer consists of 1 x PBS, 5 mM EGTA, 1 % Triton 
X, PIC 1 : 50 and PMSF 1 : 100). 
 
 
27 
 
2.6 Pulldown assay 
Cell lysate from BHK cells expressing GPF tagged KRASG12D was incubated with 
GST-RBD beads with or without compound, for 2 h at 4°C.  The first step to prepare the 
cell lysates was to trypsinize cells in a T75 flask.  Next, the cells were separated and 
centrifuged at 1,000 rpm for 5 min and the media was aspirated. The cells were 
resuspended in fresh media and centrifuged again for another wash in PBS. The cells 
were centrifuged a third time and the PBS was aspirated.  Finally, cells were 
resuspended in lysis buffer and lysed by vortexing with two 10 sec pulses with a 5 min 
rest on ice between. To prepare cell lysate samples for protein assay the same protocol 
as previously described for the western samples was used (Chapter 2, Section 2.3).  For 
pulldown experiments ~420 µg of protein from the KRASG12D BHK cells and ~220 µg of 
protein from the HRASG12V cells were  used.  The samples were prepared with cell lysate, 
100 µl of 1 : 50 diluted GST-RBD beads, and binding buffer (lysis buffer lacking 
detergent) to a final volume of 1 ml. The samples were then incubated for 2 h under 
constant agitation at 4 °C.  Then samples were washed with buffer composed of 50 mM 
Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 0.1 % Trition X-100 and protease 
inhibitors. After pulldown incubation, the samples were analyzed with western blotting 
using GFP rabbit (2956S) from Cell Signaling Technology and GST mouse (B-14) from 
Santa Cruz Biotechnology. 
 
2.7 Cell proliferation assays 
For these assays, the cells were plated at 1 * 103 cell count per well in a 96 well 
plate.  To start, the cells were trypsinized, washed and counted.  After the count a 1 : 10 
dilution of cells was prepared in 10 ml of fresh media, and then 100 µl of the cell 
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suspension was dispensed per well. The plates were then incubated for 24 h at 37 ºC.  
Then the media was replaced without washing with 100 µl of media containing 
compound. Media with compound was prepared by serial dilution at concentrations 
indicated. For the lung cancer cell lines, it was determined that cells needed at least 56 
hours to double, therefore the proliferation assays were conducted for 72 h for all cell 
lines. After 48 h, the pH of the media can change, becoming toxic to cells. Therefore, 
every 24 hours the media was changed for fresh media with compound. For the 
pancreatic cancer cells, cells need 42 hours to double therefore we performed 48-hour 
incubations . At the end of the incubation the plates were washed with PBS and frozen 
at -80 oC for a minimum of 24 h. Next plates were thawed and the CyQuant dye (in lysis 
buffer provided in the CyQuantTM cell proliferation assay kit, InvitrogenTM kit) was added, 
and after a five-minute incubation fluorescence (excitation: 480 nm excitation: 520 nm) 
was measured with a Tecan Infinite M200 plate reader.  
Additionally, cell counting experiments for pancreatic cancer cell lines (Miapaca-
2 and Bxpc-3) were conducted in 12-well plates.  Cells were seeded at 2.6 * 104 cells per 
well for Miapaca-2 and 5.2 * 104 cells per well for Bxpc-3. Compounds were prepared in 
full serum media by 8-point serial dilution and the compound- or vehicle-containing media 
was changed every 24 h.  After 72 h, the cells were trypsinized and counted in Trypan 
Blue using Countess (InvitrogenTM).  
 
2.8 NMR  
The Putkey lab used bacteria (BL21) to express KRASWT labeled with N15 [82].  The gene 
construct was codon optimized to maximize expression and included an N-terminal His 
tag with a TEV cleavage site to facilitate purification. With this system they were able to 
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recover approximately 30 mg of KRAS per liter of culture [82].  We then took 2D [H1 N15] 
HSQC spectra, which showed the amide chemical shift cross-peaks, and determined the 
prevalence of an ordered conformation of the bacterial expressed KRASWT [82]. 
Compounds were added to the NMR solution with KRAS and data amide chemical shift 
perturbations were collected to determine compound binding. 
 
2.9 Microscale thermophoresis (MST)  
Determination of dissociation constants using MST was performed following 
vendor protocols. Purified KRAS was labeled with the Monolith MTTM Protein Labeling 
Kit RED-NHS (NanoTemper Tech) through buffer-exchange in the labeling buffer (40 
mM HEPES, pH 7.5, 5 mM MgCl2, 500 mM NaCl). The concentration of the eluted protein 
was adjusted to 2-20 µM, the dye added at a 2-3-fold concentration to a final volume of 
200 µL, and the mixture incubated for 30 min at room temperature in the dark. Labeled 
KRAS was purified using the column provided in the kit. For MST measurements, a 16-
point serial dilution of ligand was prepared in an MST assay buffer (40 mM HEPES, pH 
7.5, 5 mM MgCl2, 100 mM NaCl, plus 0.05% Tween-20 and 2-4% DMSO), and added to a 100 
nM KRAS solution. The solutions were loaded in capillaries and measurements were done at 
room temperature using 20% LED and 40% MST power. The data were fit in Igor Pro using the 
Hill equation. 
 
2.10 Nucleotide exchange and release assays  
Loading of fluorescent-labeled GDP (BODIPY-GDP; BGDP from hereon) to KRAS 
was conducted following previous reports [118; 128] , with minor modifications. Purified 
KRAS was buffer-exchanged in NAP-5 column (GE Life Sciences) in low Mg2+ buffer (25 
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mM Tris pH 7.5, 50 mM NaCl, and 0.5 mM MgCl2). The eluate was incubated with 10-
fold molar excess of BGDP (Life Technologies) in the presence of 5 mM EDTA and 1 
mM DTT for 1.5 h at 20 °C in the dark. Then 10 mM MgCl2 was added and the solution 
was incubated for 30 min at 20 °C. Free nucleotide was removed by gel filtration using a 
PD-10 column (GE Life Sciences) that had been equilibrated with the reaction buffer (25 
mM Tris-HCL pH 7.5, 50 mM NaCl, 1 mM MgCl2, and 1 mM DTT). The concentration of 
BGDPKRAS was determined using Bradford assay and a BGDP standard curve. Then the 
effect of ligands on the intrinsic rate of nucleotide release was monitored using the 
decrease in fluorescence with time as BGDP dissociates from KRAS in a 100 µL reaction 
mixture (96-well plate) of 0.5 µM BGDPKRAS, 100 µM GTP and varying concentrations of 
ligand (0 to 25 µM); GTP was added just before measurements. To measure the rate of 
SOS-mediated nucleotide release, 0.5 µM SOS (residues 564-1049, Cytoskeleton Inc) 
was added after GTP addition, and fluorescence was immediately read (excitation: 485 
nm, emission: 510 nm) using Tecan Infinite M200 plate reader. Intrinsic and SOS-
mediated nucleotide exchange rates were monitored with the fluorescence intensity 
increase of BGTP as it displaces GDP from KRAS. We used a 100 µL reaction mixture 
containing 0.5 µM each of GDPKRAS, BGTP (and SOS) plus varying concentrations of 
ligand (0 to 25 µM); BGTP was added just before measurements. Experiments were 
conducted with minimal light and the reaction was monitored for 2 h at room temperature. 
Fluorescence intensities were normalized at 120 s and the traces were fit with linear or 
single exponential functions (Igor Pro, Wavemetrics). 
 
2.11 Fluorescence polarization  
Fluorescence polarization assay was conducted following previous reports [129; 
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130]. KRAS was pre-loaded with the non-hydrolyzable fluorescent GTP analog BODIPY-
GTP--S (BGTP--S; Life Technologies) using buffer-exchange in NAP-5 (GE Life 
Sciences) as described in the previous section. Then 0.5 µM (50 µL) of BGTP--SKRAS was 
incubated with an equal volume but varying concentrations (0 to 2.5 µM) of GST-RafRBD 
(Raf RBD residues 1-149; Life Technologies) for 30 min in the dark. To determine the 
effect of ligand on RAS-Raf binding, KRAS was first incubated with a fixed concentration 
of the ligand for 30 min and then with GST-RafRBD. Fluorescence polarization was 
measured using PolarStar Optima plate reader (excitation: 485 nm, emission: 520 nm) 
at room temperature. GST-tag was used to increase the weight of RafRBD for a greater 
polarization. The dissociation constant for KRAS-Raf binding was determined using a 
quadratic ligand binding equation [129]. 
 
2.12 Raster Image Correlation Spectroscopy (RICS) analysis  
 33 mm dishes were seeded with BHK cells expressing GFP fused KRASG12D at 2 
*105 cells per dish.  After 24 h the cells were incubated with compound as indicated or 
vehicle control for 3 h in serum free media. Live cells were then imaged with a confocal 
microscope, the GFP was excited by laser at approximately 1.73 mW (excitation 488nm).  
Image analysis followed previous protocols [131].  
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Chapter 3: Inhibitors of Mutant KRAS Signaling 
3.1 Introduction 
Despite decades of effort, drugging KRAS (and RAS proteins in general) remains 
an unrealized goal [132]. Many studies have established the allosteric nature of RAS [73; 
133], and discovered several allosteric small-molecule KRAS binders [75; 77; 82; 118; 
134]. Moreover, a number of recent reports described molecular fragments [118], small-
molecules [75; 77; 135; 136], peptidomimetics [137; 138] and monobodies [36] that bind 
KRAS and modulate its functions in various ways. While this progress towards 
developing a therapeutic agent to inhibit mutant KRAS function is encouraging, to the 
best of our knowledge these compounds have not made it to clinical trial. In this chapter 
I will describe our efforts to design a novel small molecule inhibitor of mutant KRAS.  One 
of the goals of this project was to combine MD with HTVS. By doing this, we sought to 
eliminate the pitfall of docking directly on a protein structure generated by X-ray 
crystallography because surface pockets can be closed due to crystal packing.  
Described in this chapter are the details of the molecular dynamics simulations and how 
we chose a representative structure to use in a HTVS for new KRAS binders. Then the 
chapter will describe the results of a small cell-based screen of potential hits which 
yielded a new class of inhibitors.  Finally, we used a range of biophysical and cell assays 
to characterize the new inhibitors.  We found that some of these molecules bind to the 
p1 pocket with nanomolar (nM) affinity and abrogate KRAS signaling by directly inhibiting 
the interaction of KRAS with effector proteins.   
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3.2 Simulation analysis  
Allosteric pockets on the surface of KRAS are not usually apparent or available 
for docking in the structural conformations generated by X-ray crystallography. To reveal 
pockets, Dr. Priyanka Prakash, a researcher from our lab, conducted molecular dynamic 
simulations of GTP bound KRASG12D with Nanoscale Molecular Dynamics (NAMD) using 
the Charmm27 force field [139; 140]. The simulation Dr. Prakash generated for this study, 
involved KRASG12D in a typical solvent environment with the addition of small probe 
molecules [83]. During the simulation the probes interacted with the protein, non-
covalently binding to surface pockets as they open and close.  By analyzing binding sites 
and the frequency of contacts, binding hotspots were identified.  Allowing the protein to 
flex with MD simulations such as this can generate open pocket conformations for 
docking that were not initially available. Thus, we incorporated protein dynamics into the 
drug screening process and we ensured the HTVS included a protein conformation with 
largest avaialbe pockets. Therefore, with this pocket conformation we could screen a 
wider range of molecules in terms of size and configuration.  
 For the HTVS we chose to focus on pocket 1 (referred to as p1 from hereon), 
which is located in lobe 1 between the central beta sheet and switch 2, (see Figure 1.2) 
for two reasons.  Frist, the residues that compose this pocket (residues 5-7, 37, 39, 50-
56, 67 and 70-75) are vital to KRAS effector binding. Residues 37, 38, 39, 41, and 54 
are important for interactions with downstream effectors, such as RAF, while residues 
36, 37, 38, 67 and 70 are important for interactions with GEFs, such as SOS [1].  
Therefore, a molecule that binds to this pocket could potentially interfere with the 
interaction between KRAS and some direct effectors or SOS.  Second, the presence and 
location of the p1 pocket was experimentally validated by others using multi-solvent or 
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crystal soaking techniques to generate crystal structures with a small molecule bound to 
KRAS such as PDB 4DSO [69]. 
 In the next step, we determined which conformations of the protein we would use 
for docking.  This entailed evaluating over 27,000 conformations derived from the 
simulation to measure the volume of p1.  To accomplish this we used a program called 
Fpocket, which can measure the volume of a pocket in every conformation of a typical 
ensemble generated by MD simulations [141]. Another method I used to determine which 
conformation of the pocket to use for screening was conformation-based clustering.  This 
method is based on the number of unique conformations generated during the simulation 
and considers only the backbone of the protein.  Using root-mean-square deviation 
(RMSD) and a user define cutoff value, nearest neighbors of conformations within the 
cutoff value are grouped together forming a cluster.  This method allowed the entire 
simulation to be clustered into set representative conformations which contain a 
decreasing number of conformation members. The volume of p1 measured in the top 
four clusters, which represented about 90 % of the MD simulation data.  We found that 
p1 ranges in volume from 219 Å3 to 0 Å3 with an average volume of 119 Å3. Additionally, 
we found that the top four clustered conformations contained two open pocket 
conformations with p1 volumes of 180 and 120 Å3, respectively. The KRAS conformation 
in which p1 has the largest volume was selected for docking. This conformation was 
chosen for two reasons.  First it was the largest volume therefore we could increase our 
chemical search space and test a wider size range of molecules. Second, there are four 
groves between residues in which molecules could bind and interact via hydrophobic 
contacts. The grooves are between D54 and S39 (Figure 3.1 blue), S39 and E37 
(Figure 3.1, blue and green), E37 and M67 (Figure 3.1, green and turquoise) and 
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between T74 and K75 (Figure 3.1, purple).  With a representative conformation of 
KRASG12D to use for docking, the next step was to benchmark the docking program to 
determine parameters for the HTVS.  
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Figure 3.1: KRAS with pocket p1 grooves highlighted. Shown is the structure of 
KRAS in the conformation used for our HTVS. Molecules could have hydrophobic 
interactions with the four grooves of pocket p1, highlighted in blue, green, turquoise and 
purple.  
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3.3 Running and analyzing the high throughput virtual screen 
DOVIS (version 2.0) is a program that was developed to perform multiple 
AutoDock4 (version 4.0.1) runs in parallel to maximize efficiency [122; 142; 143]. We 
have DOVIS complied on our cluster, which allows us to screen over 6 thousand 
molecules per node per day.  However, before starting the screen careful benchmarking 
analysis was necessary to choose the docking parameters, i.e. the number of energy 
evaluations and the number of algorithm runs, such that HTVS returned results similar 
to posed molecules determined by X-ray crystallography, see Table 3.1 for parameters 
tested. AutoDock4 uses the Lamarckian genetic algorithm to determine the lowest 
energy binding orientation and configuration of a molecule by generating a population of 
unique individuals and testing each one in the binding site. The individuals are copies of 
the molecule with unique orientations and changes of rotatable bonds, which act as 
“traits” of the individual. The highest scoring individuals become ancestors to the 
subsequent generations, passing on to the next generation of individuals the orientations 
or bond torsions or both that resulted in high affinity interactions. The repetition of this 
process is how the algorithm determines the best pose and score for a molecule. A high 
number of population members per generation consumes energy evaluations but helps 
determine the best “genetic traits” to pass on per generation, while the number of 
generations helps determine the highest affinity pose per molecule.  The number of 
genetic algorithm runs helps ensure reproducibility of the final poses and scores.  Slightly 
reducing the parameters of the genetic algorithm that estimates the binding energy does 
not significantly change the final score (the error for the AutoDock4 free energy based 
scoring function is ~2 kcal/mol) [144]. However, increasing the genetic algorithm 
parameters of AutoDock4 increases the time of docking per ligand. The parameters that 
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were  chosen, described in the methods section, were consistent with both the 
recommendations of the developers of AutoDock4 and previously published studies 
[143].     
 
 
 Table 3.1: Testing AutoDock4 Parameters for HTVS 
 
  
Benchmark 1 2 3 4 5 
GA generation x1000 27 270 27 
GA energy x1,000,000 1 100 10 10 
0QY.pdb -5.01 -5.01 -5.40 -5.39 -5.39 
9LI.pdb -4.22 -4.22 -4.26 -4.26 -4.26 
KOB -2.99 -2.99 -3.45 -3.48 -3.48 
ZINC19991337 -8.35 -8.35 -8.92 -8.51 -8.51 
ZINC39352733 -8.24 -6.63 -8.62 -7.12 -7.12 
ZINC01328021 -8.12 -8.42 
 
-8.53 -8.53 
ZINC39362681 -8.10 -7.69 
 
-8.89 -8.89 
Time in Minutes 2 -5 420 45 35 
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From the first HTVS run we screened over 6 million compounds and selected the 
top 3,762 molecules that scored a ΔG = -6.8 kcal/mol or higher affinity. The docking 
score for these molecules ranged from -6.8 to just over -8 kcal/mol and the reported error 
in the score for AutoDock is ~2 kcal/mol, which means there is no significant difference 
in score for the top molecules.  To narrow down the list of molecules we decided on a 
consensus scoring method which involved re-screening the top molecules with VINA.  
VINA is an independent docking program that uses a different search algorithm and 
scoring method to determine pose and calculate interactions between ligand and 
receptor [123; 145]. After the VINA screen, we looked at the top 500 in each list (VINA 
and AutoDock4) and selected the molecules that overlap in ΔG.  Additionally, to validate 
that the best binders were selected we evaluated 8 ligand receptor interactions with 
BINding ANAlyzer v1.2.0 (binana) a script developed by Durant et al.  [124]. Included in 
the binana analysis of the ligand interactions with p1 residues were hydrophobic 
contacts, hydrogen bonding, pi-stacking interactions and salt bridges (see methods for 
full description). This gave us 58 molecules, which when compared to the group as a 
whole were more likely to be better binders with KRAS.  Overall, we found that this 
method helped identify molecules that were enriched for high affinity interactions. 
Additionally, this approach reduced the number of molecules that had high scores due 
to their size without making high affinity interactions with p1 residues.  Other aspects, 
such as solvent accessible surface area (SASA) were considered. However, this method 
eliminated many molecules because the pocket was very shallow and often half or more 
of the molecule was exposed. Finally, the molecules were visually inspected and based 
on binana analysis and consensus scoring we concluded that the selected 58 had a good 
mix of similarity to known binders, high affinity interactions, and drug-likeness.  
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3.4 Cell signaling assays demonstrate promising effects of compound 11 
Western blotting analysis was used to quickly assess the potential impact of our 
predicted hits on MAPK signaling, a major pathway activated by KRASG12D. Specifically, 
we monitored phosphorylated ERK levels (p-ERK) in BHK cells stably expressing 
KRASG12D treated with vehicle (DMSO), the MEK inhibitor U0125 (U) or compound at 
four concentrations (1-100 μM). The results show that the majority of the predicted hits 
have no effect while a few compounds (e.g. 4) increase rather than decrease p-ERK 
levels (Figure 3.2). Compounds 9 and 11, on the other hand, decrease p-ERK levels at 
concentrations ≥ 50 μM and ≤ 5 μM, respectively. To verify the latter observation, we 
repeated the experiments in an expanded concentration range starting from 0.1 μM. As 
in the first screen, compound 11 dose-dependently decreases p-ERK levels, leading to 
~50% reduction at 5 μM (Figure 3.2B). However, compound 9 increased p-ERK levels 
at 25 and 38 μM in contrast to the decrease observed at higher concentrations (Figure 
3.2B). Although a similar increase and then decrease of KRAS signaling with increased 
ligand concentration has been observed before (49, 52), we selected the more potent 
and monotonously dose-dependent compound 11 for further analysis.   
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Figure 3.2: In silico prediction and initial experimental characterization of potential KRAS 
inhibitors. (A) Chemical structure of eleven computationally predicted hits (compounds 1 
through 11) selected for experimental testing in cell-based assays. (B) Western blots showing 
levels of phosphorylated ERK (p-ERK) in BHK cells ectopically expressing GFP-KRASG12D 
treated with vehicle (DMSO), a positive control U (the MEK inhibitor U0125) or compound at the 
indicated four concentrations.   
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3.5 Compound 11 binds to WT and oncogenic KRAS mutants with nano-molar 
affinity.  
Figures 3.3B-C show the chemical structure and the predicted complex of 
compound 11 with KRAS, showing that the ligand forms multiple favorable interactions 
with residues in the p1 pocket.  Figure 3.3D shows that the compound binds to 
GTPKRASWT with a KD = ~0.3 µM, suggesting a very tight binding rarely seen in primary 
screens. The compound has a very similar affinity (KD = ~0.4-0.7 µM) for oncogenic 
mutants KRASG12D, KRASG12C and KRASQ61H in the GTP-bound state (Figure 3.3D). 
However, no binding was detected to KRASWT and KRASG12D in the GDP state or to our 
control Rap1B, a RAS-related small GTPase with homologous structure. Few weak-
affinity non-covalent binders that exhibit some selectively toward GDP- or GTP KRAS 
have been reported (25-27, 53). However, to the best of our knowledge, compound 11 
is the first small molecule to selectively bind to GTPKRAS with nanomolar affinity. In the 
docked pose (Figure 3.3C), the 1-piperazineethanol moiety occupies an electronegative 
cleft near D54 and D38, and donates hydrogen bonds to the side chain and backbone 
atoms of E37. The methylated pyrazolopyrimidine core sits in a trench on top of V7 and 
L56 with the methyl pointing towards I55. The pyrimidine-bound benzene occupies the 
space between the central beta sheet (β1-β3) and helix 2, making π-stacking interactions 
with Y71. The pyrazol-attached benzene is buried deep in a tight pocket, stabilized 
primarily by van der Waals interactions with side chain carbon atoms of V7, L6 and K5; 
these interactions appear to be crucial for the binding and are common in the majority of 
our predicted hits in Figure 3.3A. We propose that, in addition to potential ligand-induced 
conformational changes, the compound’s preference for GTPKRAS can be explained by 
the conformational differences of these residues in GTPRAS versus GDPRAS(5). 
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Figure 3.3: Predicted binding mode and measured affinity of compound 11 to KRAS. (A) 
Structure of the catalytic domain of KRAS used for the virtual screening. Lobe1 (residues 1-86) 
and lobe2 (residues 87-166) are highlighted in different colors, as well as switches 1 (residues 
30-40) and 2 (residues 60-75). Our target allosteric pocket p1 is indicated. (B) Chemical structure 
of compound 11. (C) Predicted binding pose of compound 11 with key polar or vdW interactions 
with the protein highlighted. (D) MST experiments (conducted and figure generated by Dr. 
Cynthia Pagba) indicating direct binding of compound 11 to KRAS, along with dissociation 
constants (KD) derived from the curves. Changes in fluorescence upon titration of 50 μM KRAS 
with increasing concentration of compound are shown: KRASWT (red), KRASG12C (green), 
KRASG12D (purple) and KRASQ61H (blue), each bound to the non-hydrolyzable GTP analogue, 
guanylyl imidodiphosphate (GNP). No binding was detected for GDP-bound KRASG12D and 
KRASWT as well as Rap1B, which was used as control.  
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3.6 Compound 11 abolishes interaction of KRAS with RAF. 
We used fluorescence polarization, pull-down assays, and FLIM-FRET to check 
if our compound inhibits RAS signaling by interfering with effector binding. Pull-down 
assays directly measure the interaction of KRAS with the RBD of RAF in purified or cell 
lysate systems, while  FLIM-FRET measures the interaction of KRAS with full-length RAF 
in the cellular milieu. Dr. Cynthia Pagba, a researcher in our lab, used fluorescence 
polarization of BGTP--S to monitor binding of the KRAS catalytic domain to GST-RafRBD 
with and without pre-incubation with 1 μM compound 11. Figure 3.4A shows a dramatic 
decrease in polarization in the entire concentration range of GST-RafRBD. For example, 
at 2 μM GST-RafRBD, compound treatment reduced the polarization and therefore RAS-
RAF interaction by >80%. The dissociation constant derived from the polarization curves 
indicate that 11 reduced the affinity of KRAS to RafRBD by ~13-fold. Consistent with this 
observation, pull-down of GFP-KRASG12D by GST-RafRBD beads show a significant (e.g. 
>50% at 1μM of 11) decrease in GFP-KRASG12D levels (Figure 3.4B). We observed a 
similar effect in FLIM-FRET experiments in cells, in which quenching of GFP 
fluorescence lifetime indicates an interaction between GFP-KRASG12D and RFP-CRAF. 
Quenching of GFP fluorescence lifetime and hence KRASG12D-CRAF interaction is 
significantly reduced upon compound treatment (Figure 3.4B). These observations are 
supported by a comparative analysis of available RAS-RAF structures and our predicted 
ligand-bound structure. Taken together, these results strongly suggest that compound 
11 will inhibit MAPK signaling by directly disrupting RAS-effector interaction.  
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Figure 3.4: Compound 11 disrupts KRAS-RAF interaction. (A) Fluorescence polarization 
(conducted and figure generated by Dr. Cynthia Pagba) of BGTP--SKRAS (0.5 µM) as a function 
of a varying concentration of GST-RafRBD in the absence (red) and presence (blue) of 1 µM 
compound 11. Shown above the curves is the KD for KRAS-RafRBD binding obtained by fitting the 
data to 𝑃 = 𝑃1 + (𝑃2 − 𝑃1)
𝐾𝑑+𝑐+𝑥−√(𝐾𝑑+𝑐+𝑥)2−4∗𝑐∗𝑥
2
, where P1 is polarization of free KRAS, P2 
is polarization of RAF-bound KRAS, c is the total concentration of KRAS, and x the total 
concentration of RafRBD. (C) Amount of GFP-KRASG12D pulled down by GST-RafRBD after 
treatment of cell lysates with compound at the concentrations indicated (representative westerns 
are shown at the top). (D) GFP fluorescence lifetime from FLIM-FRET using cells expressing 
GFP-KRASG12D alone or with RFP-RAF, with or without treatment by 1 μM compound 11. Data 
are shown as mean ± S.E; significance estimated by one-way analysis of variance.  
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3.7 Compound 11 inhibits KRAS signaling.  
Figure 3.5 shows that compound 11 dose-dependently decreases both p-ERK 
and p-CRAF levels in BHK cells expressing KRASG12D and KRASG12V, suggesting 
inhibition of RAS signaling via the MAPK pathway. The data also indicate that the ligand 
has a slightly lower IC50 for its direct effector Raf (e.g., 0.7 in the case of KRASG12D) than 
the two-steps removed ERK (1.3 μM). Note also that the IC50 for CRAF is very close to 
the KD of the ligand for GTPKRAS. Changes in phosphorylated (p-AKT) levels show that 
the compound also inhibits signaling through the AKT pathway but to a lesser extent than 
the MAPK pathway. Together, these data suggest that the ligand disrupts MAPK 
signaling by acting on RAS or its upstream modulators. Since our MST data showed that 
compound 11 binds to GTPKRAS but not GDPKRAS, we hypothesized that 11 may be less 
effective in inhibiting endogenous RAS signaling where RAS is predominantly GDP-
loaded. We tested this hypothesis using wild type (un-transfected) BHK cells and found 
no significant difference in p-ERK levels between treated and untreated cells (data not 
shown). To test if compound 11 is selective for the KRAS isoform, we measured p-ERK 
and p-CRAF levels in BHK cells expressing the constitutively active HRASG12V (Figure 
3.5, right). The data indicates no significant effect on the phosphorylation of these 
effectors and hence signaling via the MAPK pathway. Similarly, no major effect on p-
AKT levels was observed even though HRAS is a major driver of the AKT pathway.  As 
a control, treatment of the HRASG12V-expressing BHK cells with 10 μM of the MEK 
inhibitor U0126 (U) almost completely abolished MAPK signaling (Figure 3.5). In sum, 
our comparative cell signaling analyses indicates that compound 11 selectively inhibits 
signaling through activated KRAS, which is consistent with its dramatic effect on KRAS-
RAF interaction (Figure 3.4). 
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Figure 3.5: Compound 11 inhibits mutant KRAS signaling. Representative western blots 
(top) and their quantification showing levels of phosphorylated CRAF (p-CRAF), ERK (p-ERK) 
and AKT (p-AKT) in cells expressing KRASG12D (left), KRASG12V (middle) and HRASG12V (right) 
treated with the indicated concentrations of compound 11, DMSO or, where indicated 10 μM 
MEK inhibitor U0125 (U). Compound 11 dose-dependently reduced p-CRAF and p-ERK levels, 
and to a lesser extent p-AKT levels, in cells expressing KRASG12D (estimated IC50 0.7 μM for p-
CRAF and 1.3 μM for p-ERK) and KRASG12V, but not HRASG12V. Data are shown as mean ± S.E; 
significance was estimated by one-way analysis of variance: * = p < 0.02; ** = p < 0.005; *** = p 
< 0.0001.  
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3.8 Compound 11 inhibits cancer cell growth.  
A CyQuant cell proliferation assay and/or cell counting was used to test if our 
compound affects growth/proliferation of cancer cells. As test cases, we chose H1975 
and H522 (KRASWT) and SKLU-1 (KRASG12D) lung cancer cells, and Bxpc-3 (KRASWT) 
and Miapaca-2 (KRASG12C) pancreatic cancer cells. Figures 3.6 A-B show that each of 
these cell lines is sensitive to the compound, with Bxpc-3 and SKLU-1 being especially 
responsive. Consistent with the binding data (Figure 3.3 D), there is no significant 
difference in the effect of 11 on KRASWT and KRASG12D lung cancer cells. However, there 
is a typical hormesis in our Bxpc-3 data, a trend noticed in toxicology that can indicate a 
beneficial effect of a molecule at some concentrations.  The CyQuant assay measured 
DNA content as an indicator of proliferation.  We used cell counting to test if the observed 
increase in DNA content translated to cell proliferation. The result shown in Figure 3.6 
B indicates that the enhancement in DNA synthesis did not lead to enhanced cell 
proliferation.  Moreover, the compound is significantly more effective in the KRASWT 
Bxpc-3 cells than the KRASG12C MiaPaCa-2 cells, which is consistent with the difference 
in affinity for KRASG12C compared to KRASWT, observed in MST (Figure 3.6 B). 
However, given the lack of effect on RASWT signaling (Figure 3.6 D) we hypothesized 
that compound 11 could enhance interaction of KRAS with pro-death effector RASSF6. 
In pulldown experiments in Figure 3.6 C we show RASSF6 is pulled down with KRASG12D 
at high concentrations of compound 11.   Overall, however, it is clear that compound 11 
inhibits proliferation or survival of cancer cells.   
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Figure 3.6: Proliferation assays suggest that cancer cells are sensitive to compound 11.  
(A) Proliferation profile of lung and pancreatic cancer cells upon treatment by increasing 
concentration of compound 11 monitored by CyQuant assay. The lung cancer cell line with 
mutant KRASG12D (SKLU-1) is slightly more sensitive than its KRASWT counterparts H522 and 
H1975. However, the mutant KRAS (MiaPaCa-2) pancreatic cancer cell line is less sensitive then 
Bxpc-3 KRASWT pancreatic cancer cell line. (B) Proliferation profile of pancreatic cancer cells 
upon treatment by increasing concentration of compound 11 monitored by cell counting. The 
inset is the results from the CyQuant assay showing a hormesis in response to compound 11 at 
lower concentrations. Data are averages over three independent experiments and error bars 
represent standard error. (C) A representative western of pulldown assay with GST-RBD, the 
blot indicates RASSF6 is pulldown with GFP-KRASG12D at 20 μM of compound 11.  On the right 
is the quantification of the western blots.  This was preformed twice. (D) Quantification of western 
of p-ERK levels in BHKWT cells treated with compound 11, preformed in triplicate.  
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3.9 Effect of compound 11 on intrinsic and GEF-dependent nucleotide release and 
exchange reactions.  
In addition to its effect on effector binding, compound 11 also slightly reduced the 
rates of both intrinsic and SOS-mediated GDP/GTP exchange reactions of KRAS, as 
well as SOS-mediated GDP release. Figure 3.7 shows time-dependent decreases and 
increases of fluorescence intensity as a labeled-nucleotide dissociates from and binds to 
KRASWT, respectively. Compound 11 reduced the rates of both intrinsic and SOS-
mediated nucleotide exchange reactions, as well as the SOS-dependent (but not 
intrinsic) release of labeled-GDP. In particular, 11 decreased the intrinsic rate of 
nucleotide exchange by ~10-fold (Figure 3.7, top-left) but has no effect on intrinsic 
nucleotide release (Figure 3.7, bottom-left). The latter is consistent with our observation 
from MST that 11 does not bind to GDPKRASWT.  Since GTP hydrolysis is unlikely to occur 
within the timescale of our experiments [82; 146], a plausible interpretation of the former 
would be compromised GTP loading. This is possible if, for example, the ligand binds to 
the nucleotide free ‘transition state’ conformation of KRAS and induces reorganization of 
active site residues. This is supported by the fact that 11’s effect on the rate of nucleotide 
exchange is significantly smaller (only a 1.1-fold decrease, Figure 3.7, top-right). SOS 
stabilizes nucleotide free RAS in an open active site conformation [31], which allows for 
faster expulsion and rebinding of GTP or GDP. Stabilization of the KRAS:SOS complex 
could also help counteract the observed effect of the ligand in intrinsic nucleotide 
exchange, and may explain the 1.5-fold reduction in the rate of SOS-mediated GDP 
release (Figure 3.7, bottom-right).   
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Figure 3.7: Effects of compound 11 on intrinsic and SOS-mediated nucleotide exchange 
and release. (Top) Intrinsic (left) and SOS-mediated (right) rates for the nucleotide exchange 
reaction KRASGDP + BGTP  KRASBGTP + GDP in a mixture of 0.5 µM each of KRAS, BGTP, 
and SOS. (Bottom) Intrinsic (left) and SOS-mediated (right) rates of the nucleotide release 
reaction KRASBGDP + GTP  KRASGTP + BGDP. Concentrations of KRAS and SOS were 0.5 μM 
and that of GTP was 100 µM. Ligand concentrations: 0 (circle), 0.78 (square), 1.56 (triangle), 
3.12 (inverted triangle), 6.25 (left-sided triangle), 12.5 (right-sided triangle) and 25 µM (diamond). 
Intensities were normalized with respect to the value at 120 s. Linear or single exponential fits, 
starting from 120 s, were superimposed as solid lines. Inset: Calculated rates as a function of 
ligand concentration. (work and figures generated by Dr. Cynthia Pagba) 
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 Plotting the measured rates as a function of the total ligand concentration yielded 
additional insights into the effect of 11 in the intrinsic and GEF-catalyzed enzymatic 
activity of KRAS. We obtained an estimated EC50 of 3.1 ± 1.2 µM from the intrinsic 
nucleotide exchange assay, and a similar value of 5.3 ± 2.0 µM from the SOS-mediated 
GDP release assay. These values are about 10-times larger than the KD of 11 for 
GTPKRASWT, suggesting a potentially weaker binding to the nucleotide free state 
assuming that the observed effects on enzymatic activity are at least in part a result of 
binding to nucleotide free KRAS. Intriguingly, we obtained EC50 = 0.6 ± 0.1 µM from the 
SOS-dependent nucleotide exchange measurements, a value very close to the KD of 11 
for GTPKRASWT. This may reflect binding to the GTP-bound KRAS at the allosteric site of 
SOS but the resulting change in the rate is very small. In fact, all of the effects we 
observed on reaction rates are much smaller than those in KRAS-Raf interaction. 
Nonetheless, they are statistically significant and dose-dependent, suggesting that 
compound 11 modulates KRAS activation through multiple mechanisms. 
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3.10 Derivative compounds 12 and 13 give insight into structure activity 
relationships.  
To identify the chemical fingerprints of compound 11 responsible for its high-
affinity binding and dual-effect on KRAS function, we studied compounds 12 and 13. 
Obtained from similarity searches based on 11, these analogues provided invaluable 
insights into the mechanisms of action of our pyrazolopyrimidine-based ligands. The 1-
piperazineethanol functional group in 11 is replaced by 1-methylpiperazine (Figure 3.8 
A & B) in compound 12. As a result, it is more hydrophobic and therefore less soluble in 
DMSO.  Nonetheless, at a somewhat higher concentration of 2 μM, 12 significantly 
reduced the p-ERK levels, but had no effect on the p-cRaf levels (Figure 3.8 C). This 
suggests a different mechanism of inhibition compared with compound 11. We confirmed 
this by FLIM-FRET, which shows that, unlike 11, compound 12 does not affect KRAS-
Raf interaction (Figure 3.8 D). Consistent with its lack of effect on effector binding, 
compound 12 is less effective in inhibiting cell proliferation (Figure 3.8 E). For example, 
the IC50 of growth inhibition for the five cancer cell lines is ~3 to >30 μM for compound 
12 compared with 2-5 μM for compound 11. Clearly 12 exhibits a better selectively profile, 
even if the estimated IC50 in each case might be an upper bound due to the low solubility 
of the compound. 
Despite the many attractive features of compound 12 as described above, a 
compound with a better solubility profile would be desirable. Also, we reasoned that a 
derivative that preserves 11’s effectiveness in inhibiting effector binding would make for 
a better lead compound. Compound 13 (Figure 3.8 A & B) satisfies both of these 
conditions: it has a methyl group attached to the pyrimidine in place of the benzene ring 
found on 11, which makes less hydrophobic and readily soluble in DMSO and other 
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common solvents, and inhibits KRAS-Raf interaction (see below).  Since soluble 
compound 13 is much more amenable for a detailed biophysical characterization than 
12, Dr. Pagba measured the KD of its interaction with G12D and other KRAS mutants 
using MST. The results summarized in Figure 3.8 C show that this compound has a 6.5-
7.1-fold weaker affinity for KRAS than compound 11. Similar to compound 11, however, 
13 does not bind to GDPKRASWT or GDPKRASG12D.  
  
55 
 
 
Figure 3.8: The piperazineethanol moiety of compound 11 is critical for abrogating effector 
binding.  (A) Chemical structure of compounds 12, an analogue of 11 lacking the terminal methyl 
alcohol functional group. (B) Predicted binding pose of compound 12. (C) p-ERK and p-cRaf 
levels in BHK cells expressing KRASG12D treated with indicated concentrations of compound 12 
or vehicle. (D) GFP fluorescence lifetime from FLIM-FRET using cells expressing GFP-KRASG12D 
alone or together with RFP-cRaf, with or without treatment with 2 μM compound 12. (E) 
Proliferation profile of lung cancer cells upon treatment with increasing concentration of 
compound 12, monitored by a CyQuant assay. Data are averages over three independent 
experiments and error bars represent standard error.  
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We used fluorescence polarization and pull-down assays to test the functional 
implication of the modification in compound 13 relative to the parent compound 11. 
Figure 3.9 D shows that 20 µM of 13 disrupts the interaction of KRAS with GST-RafRBD 
as effectively as the parent compound. The pull-down assay led to the same conclusion: 
compound 13 disrupts KRASG12D-RafRBD interaction (Figure 3.9 E). These results 
demonstrate that modifications can be made on the pyrazolpyrimidine core to optimize 
for potency and selectively without compromising effect on effector binding.   
We then wondered if interactions with switch 2 residues may play a role in 
nucleotide release, because the conformation of many switch 2 residues, such as Y71 
and Y64, differs between free and GEF-bound RAS (24-26, 54). To test this, Dr. Pagba 
measured the intrinsic and SOS-dependent rates of labeled-GDP release in the absence 
and presence of compound 13. We found that, indeed, replacing the benzene ring on the 
pyrimidine core by methyl dramatically altered the effect on nucleotide release. Whereas 
compound 11 had no effect on intrinsic and only modestly decreased the rate of SOS-
mediated nucleotide release, compound 13 dramatically increased both rates (Figure 
3.9 F). This result demonstrates that interaction with switch 2 residues including Y71 
determines how a p1-bound ligand affects GEF activity.   
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Figure 3.9: Interaction with switch 2 residues is important for modulating exchange factor 
activity.  (A) Chemical structure of compounds 13, an analogue of 11 without a benzene on the 
pyrimidine core. (B) Predicted binding pose of compound 13. (C, D) Fluorescence intensity (C) 
and KD obtained from MST experiments on KRAS mutants and control. See legend of Figure 2 
for additional details. (D) Fluorescence polarization of BGTP--SKRAS (0.5 µM) with increasing 
concentration of GST-RafRBD in the absence (red) and presence (green) of 20 µM compound 13. 
(E) Level of GFP-KRASG12D pulled down by GST-RafRBD after treatment of whole cell lysates with 
10 µM of compound 13 (representative western blots are shown at the top). (F) Intrinsic and 
SOS-mediated nucleotide release from KRAS in a mixture of 0.5 µM KRAS (and SOS), 100 µM 
GTP and 0 or 50 µM of compound 13. (Parts C, D and F work and figures by Cynthia Pagba)  
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3.11 Conclusion 
In the work described in this chapter, we used structure based computational 
design followed by biophysical and cell biological experiments to discover a novel high-
affinity KRAS inhibitor that has unique structural features.  Compound 11 non-covalently 
binds to KRAS at allosteric site p1 with nano-molar affinity, abolishes interaction with 
Raf, and slightly decreases both intrinsic and SOS-mediated nucleotide exchange 
reactions. This compound inhibits KRAS signaling and proliferation of KRAS-dependent 
cancer cells. We also discovered two analogues of compound 11 that bind KRAS with 
somewhat weaker (low µM) affinity but exhibit a remarkable capacity for selectivity. The 
compounds inhibit KRAS signaling via dramatically different mechanisms, which we 
traced back to specific protein-ligand interactions. This diversity in structure-activity 
relationship provides an ideal platform for further optimization of our highly promising 
lead compounds.    
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Chapter 4: A Second Screen for KRAS Binders 
 
4.1 Introduction 
During the HTVS for inhibitors we conducted some in vitro cell-based and 
biophysical assays on a handful of high scoring compounds to develop our approach for 
validating the HTVS hits. During these validation experiments we found one molecule, 
which will be referred to as M1, that decreased p-ERK levels in KRAS mutant cells and 
bound to KRAS as indicated by NMR (to be discussed later). From these results we 
initiated a similarity search of the PubChem database based on M1, with a Tanimoto 
threshold of 90%. The search yielded a new small library of ~3,000 similar drug-like 
molecules. These molecules were then screened against the same conformation of GTP 
bound mutant KRASG12D that was derived from a MD simulation. For this screen we again 
focused on pocket p1, which is located between switches 1 and 2 of KRAS. The 
PubChem molecules were docked with Autdock4 and then redocked with VINA to get a 
consensus score of high affinity binders. The top hits were analyzed as described 
previously and 42 were selected as potential hits from which we were able to procure 13 
for a cell-based screen.  This process allowed us to to test this method to generate 
additional binders and to generate additional data for optimization methods.  
  
60 
 
4.2 Cell-based screen of M1 similarity hits.  
We screened the top 13 hits with a monoclonal BHK cell line that ectopically 
expressed GFP-KRASG12D to identify molecules that decrease p-ERK levels. To reduce 
background ERK phosphorylation due to endogenous KRASWT we used serum free 
media. Additionally, to identify compounds that caused an acute decrease in p-ERK, 
which would indicate disruption of effector binding, we choose a 3 h incubation (see 
methods for full description of the screening procedure).  The westerns in Figure 4.1 
show the results of the screen and the corresponding compound structures. For 
compound M3 we observed a strong dose dependent decrease in KRAS signaling at 20 
and 50 μM. However, during the second round of testing with more concentrations we 
observed the effect on signaling to be inconsistent.  Our data indicates a 30% decrease 
averaged over multiple trials. Many of the other compounds either had no observable 
effect on KRAS signaling or enhanced p-ERK at the higher concentrations. This increase 
in signaling for some molecules correlated with changes in cell morphology that indicated 
toxicity.  Therefore, we concluded that enhanced signaling was induced by toxicity, rather 
than the molecule’s  specific effect on KRAS. For other molecules we hypothesize the 
increase indicates hormesis, which can also indicate the compound binds to more than 
one target and the dominate effect changes with concentrations [147].  Consistent with 
this phenomena M1 increased p-ERK during a short incubation experiments and 
decreased p-ERK during a long incubation experiments.  As part of this hypothesis we 
are extrapolating that the time difference is equivalent to a concentration difference.  
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Figure 4.1: Cell-based screen of 13 structurally similar compounds. Chemical structures 
and accompanying western blots showing levels of phosphorylated ERK in BHK cells after 
treatment with compound for 3 h in serum free media.  The BHK cells ectopically express GFP-
KRASG12D.  Indicated concentrations are in μM with negative control indicated as 0 (DMSO 
vehicle) and the positive control indicated as U (MEK inhibitor U0126 at 10 μM).    
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4.3 Biphasic effect on KRAS signaling.  
A previous lab member, Dr. Hocker, and a Hancock lab member, Dr. Cho,  
showed that a class of small molecules called Andrographolides inhibit SOS-mediated 
nucleotide exchange of KRAS in a BHK cell-line expressing KRASG12V [82]. They 
demonstrated that as a result of this inhibition p-ERK levels were reduced. However, it 
is known that KRASG12V and KRASG12D  are insensitive to GAP mediated GTP hydrolysis 
and that the rate of GTP hydrolysis is slowed significantly in mutant KRAS [117]. 
Therefore, to measure effects on KRAS signaling caused by SOS inhibition they required 
an incubation period of 48 h. We have tested M1 in a similar 48 h incubation experiment 
with the BHK cells expressing KRASG12D used for this screen. The results of these 
assays, shown in Figure 4.2, indicate a dose dependent decrease in p-ERK levels (by 
~80% relative to the vehicle control), with an estimated IC50 of 40 μM (estimated by Prism 
GraphPad 4-parameter fit). Additionally, our western data indicates a decrease in p-AKT 
levels by ~80% relative to the vehicle control. (Figure 4.2).  We hypothesize this 
compound may disrupt GEF interaction and binding of PI3K but not RAF interaction.   
Interestingly, M1 produced an ~0.8-fold increase in p-ERK levels after a 3 h incubation 
during the primary screen at all concentrations tested. When we followed up the primary 
screen with additional short incubation experiments that included KRASWT cells as a 
control, our results indicated M1 enhanced KRASG12D signaling at the lowest 
concentration tested, but no change is observed in KRASWT (Figure 4.2). The observed 
increase prompted us to hypothesize that this compound may enhance dimerization of 
KRASG12D or enhance effector interactions. 
63 
 
 
Figure 4.2 Compound M1 effect mutant KRAS signaling in short and long incubations. (A) 
Representative western blot showing levels of phosphorylated ERK (p-ERK) in BHK cell treated with 
compound M3 at concentrations indicated. The average relative level of p-ERK is indicated at the bottom 
of the blot. (B) Representative western blot showing effect of compound on mutant KRAS signaling 
pathway output on p-cRaf and p-ERK after 3 h incubation (top).  (Bottom) Representative western blot 
showing the effect of M1 on the levels of p-AKT and p-ERK after 48 h incubation.  Quantification of p-AKT 
and p-ERK (left), relative to the 0 concentration (vehicle) with positive control Fendiline (15 μM), the error 
bars representing the standard error of the mean for 2 replicate experiments. (C) The quantification of p-
AKT and p-ERK levels from untransfected BHK cells after 3 h incubation with M1 in full serum media. (B 
& C) The negative control is the 0 concentration (vehicle) and the positive control is U (MEK inhibitor 
U0126), the error bars represent standard error of the mean for 3 replicate trials.  
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To test for enhanced effector binding, we conducted two experiments, the first 
was FLIM-FRET with GFP tagged mutant KRASG12D and RFP-CRAFWT and the second 
was GFP-KRASG12D pulldown with GST-RBD (as described in chapter 3).  The results of 
the FLIM-FRET assay indicated there is no disruption of Ras-Raf interaction during 3 h 
incubation, but there is a slight disruption of the interaction upon 48 h incubation of cells 
with compound M1 (Figure 4.3). The 48 h experiment data for FLIM-FRET is consistent 
with the signaling results seen by western blot.   
For the pulldown assay we incubated cell lysate from BHK cells expressing GFP-
KRASG12D with GST-RBD on glutathione agarose beads for 2 h with or without compound 
M1.  The results of the pulldown assay to-date show a trend of increased KRAS pulldown; 
however, these experiments remain unfinished. In Figure 4.3 there is a dose dependent 
increase in KRAS pulldown with increasing concentration of compound M1.  The data 
could indicate that this compound somehow enhances the interaction between KRASG12D 
and the RBD. However, the magnitude of GFP-KRASG12D pulldown varied with each 
experiment generating a large error. Considering the variability in the pulldowns, we 
interpret these findings that increased signaling at low concentrations of M1 may not be 
a result of directly enhancing the interaction between KRASG12D and its effectors.    
 
4.4 RICS analysis indicates M1 enhances oligomerization.  
To determine if M1 causes an enhancement of dimerization KRASG12D we 
performed Raster image correlation spectroscopy (RICS) on compound-treated 
KRASG12D cells (Figure 4.3C). This work was done by Dr. Suparna Sarkar-Banerjee, a 
post-doctoral research in our lab. Specifically, we treated BHK cells expressing GFP-
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KRASG12D with M1 at 50 μM for 3 h in serum free media. Time of diffusion data from 
microscopy images was analyzed to determine the oligomerization state of GFP-
KRASG12D with comparisons made between compound treated and vehicle treated 
control cells.  The diffusion coefficient of the treated cells was lower than the control cells, 
suggesting their slower diffusion dynamics was due to higher order structures (Figure 
4.3C). The results indicate that for control cells GFP-KRASG12D exists mostly as 
monomers and some dimers, whereas the treated cells had a mixture of dimers, trimers 
(most common) and higher order oligomers. Our results show that when cells were 
treated with 50 μM of compound M1, there was an increased number of oligomers and 
a decreased number of monomers of GFP-KRASG12D.  This suggests that M1 is 
enhancing dimerization and higher order oligomerization of GFP-KRASG12D and 
enhanced dimerization could cause the increased signaling as seen in western blots 
[148].  
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Figure 4.3: FLIM-FRET and RICS analysis of M1. (A) FLIM-FRET with BHK cells transfected 
with RFP-cRAF
WT
 and GFP-KRAS
G12D
 and incubated with M1 for 3 h or 48 h.  (B) Representative 
western blot of an active GFP-KRAS
G12D
 pulldown assay with GST-RBD. The concentrations are 
ranged from 1 to 50 μM as indicated by the blot and quantification below. (C) RICs analysis (work 
and figures by Suparna Sarkar-Banerjee) of BHK cells expressing GFP-KRAS
G12D
 after 3 h 
incubation with M1 at 50 μM.  
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4.5 Nucleotide exchange data indicates biphasic response with increased 
concentrations.  
Next, we tested the hypothesis that M1 disrupts SOS interaction or nucleotide 
exchange with intrinsic and SOS mediated nucleotide exchange assays. The intrinsic 
nucleotide exchange assay used BGTP and monitored a change in fluorescences when 
bound to KRAS. We found that as the concentration of M1 increased the rate of uptake 
of BGTP also increased relative to the vehicle control (Figure 4.4).  This indicates that 
M1 binds to KRAS and enhances GTP loading. Second, in a similar assay that included 
SOS, an enzyme that catalyzes GDP release, we observed an increase in uptake 
followed by a decrease in the rate of BGTP loading.  This data could indicate that M1 
binds to SOS and enhances activity, which is consistent with other reports of a  small 
molecule that bind SOS near the catalytic site and enhance nucleotide exchange of 
KRAS [128]. The increase in GTP loading at lower concentrations was consistent with 
our short incubation signaling data at similar concentrations (Figures 4.2 & 4.4B).  
Enhanced GTP loading, even in the case of mutant KRAS, can increase signaling. 
However, during long incubation with M1 in BHK cells at 100 µM we see a decrease in 
KRAS signaling by western blot, a result that is consistent with the decrease in nucleotide 
exchange at high M1 concentrations (50 μM in these experiments).  The disruption of 
SOS mediated GDP turnover could result in less active KRAS in the cells. This would 
subsequently decrease KRAS signaling, a result that is consistent with our signaling data 
(Figure 4.2B, bottom).  
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Figure 4.4: M1 changes nucleotide exchange (A) The rate of GTP binding during intrinsic 
nucleotide exchange is enhanced with M1.  (B) The rate of SOS catalyzed nucleotide exchange 
is demonstrating that M1 could enhance the level of GTP bound KRAS at low micromolar 
treatment. The rate of nucleotide exchange then reverses at high concentrations of M1 indicating 
M1 also inhibits SOS activity. (work and figures by Cynthia Pagba)  
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4.6 Pancreatic cancer cell proliferation is reduced by M1.  
To test compound M1 in human cancer cells we chose a panel of 3 lung cancer 
cells including H522 and H1975 (both expressing wild type KRAS) and SKLU-1 cells 
which express KRASG12D.  Although these experiments remain unfinished, the data 
shown in Figure 4.5 indicate some reduction in growth at the highest concentration 
suggesting that these cells are sensitive to this compound.  Additionally, we tested 
compound M1 with two pancreatic cancer cell lines, Miapaca-2, (driven by KRASG12C) 
and Bxpc-3, which are wild type for KRAS. The compound inhibited growth of Miapaca-
2 cells with an IC50 of 6.8μM (Figure 4.5A, left). Therefore, this led us to hypothesis that 
KRASG12C may be the best target for this compound. Indeed, this compound shares 
~73% similarity with compound 21S (PDB 4M1Y), a molecule that covalently binds to 
KRASG12C and was developed by Ostrem et al. (ref). 
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Figure 4.5: Cancer cell proliferation reduced by M1 (A) (left) Pancreatic cancer cells were 
treated with M1 for 48 h and then cell proliferation was measured with CyQuant assay.  With an 
estimated IC50 of 6.6 μM the KRAS mutant dependent MiaPaCa-2 cell line is more sensitive to 
M1 then the KRASWT Bxpc-3 cell line (estimated IC50 24 μM).  Relative proliferation is plotted with 
error bars representing the standard error of the mean for two trials with three replicate wells per 
trial. (A) (right) A panel of 3 lung cancer cell lines treated for 72 h with indicated concentrations 
of M1. 
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 4.7 Biophysical assays indicate M1/KRAS binding.  
Compound M1 was subject to a small battery of biophysical assays starting with 
microscale thermophoresis (MST), which indicated high affinity binding with an initial KD 
of ~2 μM. Compound M1, is seen in its predicted binding mode in Figure 4.6 A. The 
central indazol core that sits in the space between the effector loop and switch 2 is similar 
to some known binders that disrupt GEF-mediated nucleotide exchange [118].  However, 
attached to that core structure is a unique piperazine moiety that hydrogen bonds with 
E37 holding the molecule tightly in the pocket.   
Second, in work done by Dr. Wang, a research scientist in Dr. Putkey’s lab, we 
have used NMR to determine the binding site of this molecule. Starting with N15 labeled 
GDPKRASWT we were able to generate a Heteronuclear Single Quantum Coherence 
(HSQC) spectra of KRAS shown in Figure 4.6 B.  The H1 and N15 cross peaks generated 
by amide chemical shifts attribute to the protein backbone amides and spreading of cross 
peaks in the nitrogen dimension and hydrogen dimension indicates uniform average 
structure.   
We then titrated in compound M1 to a final molar ratio of 10 : 1 of compound to 
protein and observed amide chemical shifts perturbations in residues 37, 74 and 75. 
Interestingly, there were further perturbation in those residues as the concentration of 
compound increased.  The amide chemical shift perturbations at the p1 pocket site could 
be the result of M1 binding thus validating the success of our focused design efforts with 
the HTVS. In Figure 4.6 A the pose of molecule M1 in pocket p1 is shown.  Major 
residues of the pocket were labeled and those highlighted in red showed the greatest 
amide chemical shift perturbation. The image in Figure 4.6 B is of HSQC spectra of 
amide chemical shift cross peaks generated by GDPKRASWT with M1 at three 
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concentrations.  The starting spectra, shown in blue, was taken before the addition of 
compound and then the purple at 5 : 1 and the red at 10 : 1, compound to protein molar 
ratio. 
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Figure 4.6: NMR confirms predicted binding mode of M1.  (A) Predicted binding mode of 
compound M1 in a conformation of pocket p1 of KRASG12D that was used for docking and 
generated by MD simulations.  A hydrogen bond with E37 is highlighted in yellow and the 
residues of the pocket are labeled in black.  Key residues that coincide with those that exhibited 
amide chemical shifts in NMR are highlighted in red. (B) An overlay of three NMR, HSQC spectra 
of H1 and N15 labeled KRASWT alone and then with the addition of increasing molar ratios of 
compound M1.  The blue spectra is from KRASWT alone and the purple is with the addition of M1 
at 5 x KRASWT and the red is M1 at 10 x KRASWT.  The insets show amide chemical shifts 
pertubations detected in p1 residues glycine 75 (top), tyrosine 74 (middle) and glutamate 37 
(bottom).  
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4.8 Conclusion 
A pilot screen of a few molecules during the HTVS generated a potential new hit, 
compound M1, which was used as the basis for a smaller similarity-screen for novel 
KRAS inhibitors.  Over 3,000 similar molecules from PubChem were screened through 
pocket p1 of KRASG12D.  After redocking and analysis we ordered the top 13 available 
molecules to test in cell-based and biophysical assays.   From testing we were able to 
identify 1 new potential inhibitor and determine that the parent compound M1, 
demonstrates a biphasic effect on KRASG12D signaling.  Although the new inhibitor 
proved inconsistent, the data generated to-date with M1 indicates that it binds to KRAS 
and alters signaling.  However, with SOS mediated nucleotide exchange assays we 
observe an increase in BGTP binding suggesting M1 may also be bind to SOS.  
Additionally, at low micro-molar concentrations and during short incubations we 
observed elevated KRAS signaling in western blotting as shown by increased p-CRAF 
and p-ERK levels. These results are consistent with enhanced SOS mediated KRAS 
activation and enhanced dimerization observed by RICS analysis.  We interpret this 
result as a hormesis response, in which many small molecules can have different effects 
on cells depending on concentration. The hormesis response is hypothesized to be 
attributed to a molecule binding two targets.  Our NMR results confirm M1 binds to KRAS, 
while results from the nucleotide exchange assay may indicate M1 binds to SOS.  
Therefore, at low concentrations M1 may target SOS first, then at high concentrations it 
targets KRAS. 
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Chapter 5: Discussion and Future Directions 
 
5.1 Discussion 
Breaking through the “undruggable” wall to reach KRAS has been a major 
challenge in the search for cancer therapies. Previous attempts at therapeutically 
attacking KRAS focused on inhibiting farnesyl transferase (FTI’s), which prevented the 
farnesylation and membrane anchoring of KRAS.  Although initially effective in studies, 
FTI’s ultimately failed in clinical trials [40].  It was later discovered that KRAS can be 
alternatively lipid modified by the geranylgeranylation, which bypasses the need for a 
farnesyl group as a lipid anchor [51].  More recent efforts focused on the dynamics of 
KRAS and revealed allosteric pockets suitable for binding of small molecules [20; 73]. 
Ground breaking fragments, such as DCAI and the fragment-like molecule developed by 
Sun et al., were shown to bind to p1 and disrupt KRAS interaction with SOS [118]. 
Further, small-molecules such as p4 binding andrographolides will decrease SOS 
mediated nucleotide exchange, ultimately resulting in decreased signaling through a 
buildup of GDP bound KRAS [77; 82].  The Kobe molecules were shown by X-ray 
crystallography to  bind to p1 and decrease KRAS signaling though disruption of effector 
binding [75]. However, thus far none of these ligands have led to a viable lead compound.  
Our approach to structure-based drug design for new KRAS inhibitors combined 
MD simulations with HTVS of “drug-like” molecules.  By starting with MD simulations of 
KRASG12D we were able to identify conformations of the protein with open pockets that 
were not available in starting crystal structures at the time. Our efforts led to the 
identification of a small molecule, compound 11, which directly binds KRASG12D and WT 
KRAS with nanomolar affinity. Compared with published KRAS binders that target pocket 
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p1 (25, 26), compound 11 (2-[4-(8-methyl-3,9-diphenyl-2,6,7-triazabicyclo[4.3.0]nona-
2,4,7,9-tetraen-5-yl)piperazin-1-yl]ethanol) exhibits a number of unique structural and 
biochemical properties. First, compound 11 is more drug-like (drug-likeness = 4.1) and 
more polar with 6 hydrogen bond donors and 2 acceptors (cLogP = 0.87). Second, it has 
a pyrazolopyrimidine core rather than indole or imidazole rings common in the published 
ligands. Thirdly, compound 11 is relatively large (415 Da) with its pyrazol ring methylated 
and benzoylated and its pyrimidine ring beta-modified by benzene and 1-
piperazineethanol. This allows 11 to make more extensive contacts with KRAS residues 
than is common in most of the previously published ligands (Figure 3.3C). Biochemically, 
compound 11 inhibits MAPK signaling by almost completely abrogating interaction with 
effector proteins (Figure 3.4), in contrast to many published KRAS ligands that primarily 
affect GEF activity (24-26). In Figure 5.1 we aligned the KRASG12D conformation that 
was used for docking with docked pose of compound 11, to an HRAS:CRAFRBD 
complexed crystal structure (PDB 4G0N) [149]. This alignment shows that pocket p1 of 
HRAS is open and the side chains of each residue are in very similar arrangement with 
the KRASG12D conformation.  This suggests that we have captured a potentially 
necessary conformation of KRAS for effector interaction in our simulation. Compared to 
other known binders the piperazineethanol group is a new feature, essentially it is a bulky 
ring structure that fills the space between E37 and S39 potentially limiting their 
movement. Together, the piperazine and the ethanol form two hydrogen bonds with E37, 
or alternately one with S39 and one with E37.  In this alignment, 11 would prevent the 
interaction between KRAS and CRAF because it clashes with R67 of CRAF. Further, our 
testing confirms the other hallmarks of binding to pocket p1 on KRAS are intact, 
specifically nucleotide exchange by SOS is decreased. We also see this compound alters 
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the nucleotide free state of KRAS and decreases its affinity for GTP, but does not disrupt 
GDP release [150; 151].   
Additionally, compound 11 is toxic to human cancer cells with great potency and 
for some cancer types it discriminates between KRASmut cells and wild-type dependent 
KRAS cells, albeit weakly.  Finally, the toxicity observed in cells may not be solely caused 
by off target effects. We predict this compound switches KRAS signaling from pro-
survival to pro-apoptosis by enhancing interaction with RASSF6, an effector of KRAS 
that initiates apoptosis through the MOAP/Bax pathway [152; 153].  A prediction that is 
supported by our data showing enhanced pulldown of RASSF6 (Figure 3.6).   
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Figure 5.1: KRASG12D with compound 11 docked aligned to crystal structures of RAS and 
effector complexes. (A) Superimposition of the X-ray structure of the HRAS:Raf complex (PDB 
4G0N, green and yellow) with our predicted KRAS-compound 11 complex (KRAS in cyan and 
ligand in yellow). The ligand clashes with residues R59 and R67 of Raf and competes for H-
bonding to E37, and potentially blocks the interaction between R89 of Raf and D38 of 
RAS.KRASG12D aligned with HRAS:Raf cocrystal. (B) Superimposition of the structure of 
HRAS:SOS complex (PDB 1BKD, coral and gold, respectively) and predicted KRAS-compound 
11 complex (cyan and yellow, respectively). Notice the significant overlap between the core of 
compound 11 (especially the pyrimidine-bound phenyl ring) and SOS, consistent with the 
observed reduction in the rate of SOS-mediated nucleotide exchange and release reactions 
shown in Figure 3.7. Also, note the potential of the ligand to form hydrogen bonds with H911 
and Y912 of SOS, which may explain the enhanced rate of SOS-mediated nucleotide release 
observed in compound 13 that lacks the ring clashing with SOS.  
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A second compound to come out of the primary screen was M1, which 
demonstrated binding to KRAS in NMR experiments.  This compound contains an 
indazole core that is a little more similar to other published binders than the compound 
11 core. The molecule M1 (azepan-1-yl-[1-methyl-5-[4-[(E)-3-phenylprop-2-
enyl]piperazin-1-yl]-4,5,6,7-tetrahydroindazol-3-yl]methanone) has a drug-likeness 
score of 2.9, with 6 hydrogen bond donors and 1 acceptor, the molecule weight is 462 
Da.  Compared to compound 11 this compound has demonstrated a biphasic effect of p-
ERK levels and was less potent at decreasing p-ERK levels and inhibiting cancer cell 
growth.  However, during long incubation, at all concentrations, it caused a consistent 
decrease in p-AKT levels.   
To gain insight into the structural basis for our biochemical data we superimposed 
KRASG12D with M1 docked onto crystal structure of RAS in complex with effectors. The 
docked pose of compound M1 was align with the crystal structure of  HRAS:RBD of cRaf 
(PDB 4G0N) (Figure 5.2) [149].  For compound M3 the piperazineethanol found in 
compound 11 is replace with a carboxamide group. Without a bulky group to fill the space 
between S39 and E37 and the loss of hydrogen bonds to those residues, M1 may not be 
able to interfere with R67 nor R59 of Raf.  Therefore, it probably cannot disrupt KRAS 
interactions with CRaf, like compound 11.  This conclusion is supported by our signaling 
and FLIM-FRET data (see Figure 4.2 & 4.3 A).  Similarly M1 docked on KRASG12D was 
superimposed on to the HRAS:PI3K crystal structure (PDB 1HE8 Figure 5.2 A). M1 
interacts with switch II and effector loop residues which could limit their rearrangement 
and it could clash with K223 of PI3K preventing a hydrogen bond with E37 [154]. 
However, in this complex HRAS is bound to the p110γ subunit of PI3K and residue 223 
was mutated from valine to lysine. The authors describe this change as analogous to 
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endogenous K206 of the p110α subunit that typically binds KRAS [154].  Therefore, I 
docked M1 on to HRAS in this complex and then superimposed a crystal structure of the 
p110α (PDB 4TUU) subunit [155].  Shown in Figure 5.2 A, although the full side chain 
of K206 is not present, M1 (shown in blue docked on HRAS) forms a hydrogen bond with 
S39 that would prevent K206 from interacting with E37.  The score for this pose is not 
significantly lower than the pose on KRAS (Figure 5.2 (A) M1 is in green). The position 
of the molecule and the clashes it would form with PI3K may prevent KRAS from 
interacting with PI3K, a conclusion supported by reduced cellular p-AKT levels in our 
long incubation experiments. However, binding directly to KRAS at low concentrations is 
inconsistent with our p-ERK signaling data and SOS mediated nucleotide exchange data.  
Other possibilities should be considered such as binding directly to the p110α subunit of 
PI3K and disrupting binding to KRAS. 
 M1 was evaluated in a third alignment to the HRAS:SOS crystal structure (1NVV) 
[156].  The alignment allows for a comparison of HRAS to KRAS and it is obvious that a 
significant change in the position of the switch I residues (R42 to Y32) of HRAS has 
occurred (Figure 5.2B).  However, compound M1 forms a hydrogen bond with the side 
chain of E37 which could lock the molecule and E37 together in the pocket, in this case 
it might prevent SOS activity or even binding. Additionally, a possible pi-cation stacking 
interaction with Q70 and the terminal benzene of M1 could prevent the rearrangement of 
R73 possibly eliminating a necessary stacking interaction with Y884 [128]. This along 
with a potential clash between M1 and H911 could explain a decrease nucleotide 
exchange and decreased signaling by buildup of GDPKRAS. Conversely, at low micro-
molar concentrations we observe an increase in SOS mediated nucleotide exchange.  
Recently other groups have reported small molecule that bind to SOS and enhance 
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nucleotide exchange.  The binding spot on SOS is a small pocket near the interface 
between KRAS and SOS [128]. I docked M1 on the crystal structure generated in that 
study (PDB 4NYJ) and found that the M1 fits in the pocket in a similar orientation to 2PZ 
[128].  M1 also forms a hydrogen bond with Y884 possibly stabilizing it in a pi-stacking 
interaction with R73 of RAS (Figure 5.3).  Considering our results, it could be possible 
that M1 binds to the same pocket and enhances SOS activity.  
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Figure 5.2: Compound M1 docked to KRAS and superimposed on to HRAS crystalized in 
complex with PI3K or SOS. (A) KRASG12D (blue) with M1 (green) docked is superimposed on 
to HRASG12V (purple) with M1 docked (light blue) that was cocrystalized with PI3K p110γ (green) 
(PDB 1HE8) and the crystal structure of PI3K p110α (coral color, PDB 4TV3) was superimposed 
onto the p110γ subunit.  A hydrogen bond is highlighted in yellow between M1 and the sidechain 
of S39 of HRASWT.  In the illustration only, part of K206 survived crystallization but I predict the 
end of the side chain would clash with M1 which could limit binding. (B) HRASWT (blue) 
crystalized with SOS (khaki) with KRASG12D (teal) and M1 (green) superimposed. The ligand in 
this position could limit the movement of R73, forcing it to stay extended and potentially clashing 
with Y884. This clash along with clashes with residues 912 and 911 could disrupt binding and 
therefore nucleotide exchange.   
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Derivatives of compound 11 and M1 give insight into the mechanism of activity. 
First, we tested compound 13, a derivative of 11 in which a benzene ring is replaced with 
a methyl group.  Compared to 11, we observe changes in affinity, potency and enhances 
in both intrinsic and SOS mediate nucleotide release rates. Comparison of the docked 
poses of 11 (Figure 3.3C) and 13 (Figure 3.9B) provided a rationale for the observed 
differences in binding affinity. The benzene ring of compound 11 is involved in a T-
shaped 𝜋-stacking interaction with the side chain of Y71, which is replaced by methyl in 
compound 13 so that interaction is lost.  The methyl is also too small to fill-up the space 
above Y71, which means 13 may not fit as tightly as compound 11 in the pocket and we 
then lose some hydrophobic contacts with the pocket. Additionally without this ring 
compound 13 may not clash with SOS residues H911 and Y912 thus it could actually 
then stabilize the SOS:KRAS complex.  However, we retain disruption of RAF-RBD 
binding and this is supported by our structural analysis (Figures 3.3C and 3.9B), which 
shows that compounds 11 and 13 make identical contacts with residues at the effector-
binding region via their piperazine ring and especially the piperazineethanol group.  
The predicted binding mode of another derivative, compound 12, is very similar to 
that of 11 and 13, with the key difference being that compound 12 lacks hydrogen 
bonding interactions with residues at the effector binding loop (Figure 3.5B). Specifically 
compound 12 lacks the alcohol group and therefore only forms hydrogen bonds with the 
sidechain of E37, and although we lose the effect on p-cRaf levels that 11 causes, we 
do observe a significant decrease in p-ERK levels at 2μM.   
Next for consideration is molecule M3 (1-benzyl-N,N-dimethyl-5-[2-(4-
phenylpiperidin-1-yl)ethylamino]-4,5,6,7-tetrahydroindazole-3-carboxamide) a derivative 
of M1 The docked pose is shown in Figure 5.3.  The functional features of this molecule 
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are central indazole with a piperdine, attached through an ethylamino linker, the 
piperdine makes a hydrogen bond with E37 (highlighted in yellow Figure 5.3B).  
Additionally, attached to the indazole is a carboxamide group that rests partially between 
S39 and E37 like the piperazine of compounds 11, 12 and 13. However, in contrast to 
those molecules the carboxamide cannot form hydrogen bonds with either residue nor 
does it fill up the space between residues. Therefore, the carboxamide group may be too 
small to effect S39 and E37 as significantly as the piperazineethanol of compound 11 
and 13. Similar to compound 12 we observe a small decrease in p-ERK levels but at 
more than 10-fold higher concentration, indicating the importance of the entire 
piperazineethanol moiety and the hydrogen bonds it makes. Together, these results 
indicate that the ethanol moiety on the piperazine ring, which forms a hydrogen bond 
with E37 or S39 of the effector-binding loop (Figure 3.3C), is crucial for disrupting 
interaction of RAS with CRAF. 
Further insights into the benzene to methyl change in 11 and 13 can be gained by 
considering the differences between M1 and M3 and the other three compounds.  For 
the M molecules the benzene is extended away from the central core with a linker 
attached a piperdine for M1, however for M3 the linker is between the piperdine and the 
core of the molecule, therefore the benzene becomes part of a bulkier group.  In either 
case the stacking interaction with Y71 is most likely lost.  For M3 the large piperdine-
benzene group maybe be too large to occupy the space between E37 and M67 and too 
long to fit in the pocket (Figure 5.4).  Without a trench or pocket shielding the hydrophobic 
benzene from the aqueous environment, the molecule may be too unstable to stay bound 
to KRAS except at high concentrations.  Although these compounds are capable of 
similar interactions with p1 residues as compound 11 or 13, the penalty for the solvent 
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exposed benzene and lack of additional h-bonds with S39 or E37 may be the source of 
inconsistency and low effect observed during cell-based testing. Together, these findings 
demonstrate the critical role of the benzene ring on the pyrazolopyrimidine core of 11 
and 13 plays by interacting with Y71 to enhance potency and selectivity, providing a 
useful handle for future optimization efforts. 
In summary, our comparative analyses of compounds M1, M3, 11, 12 and 13 
allowed us to unambiguously determine the mechanisms by which 11 simultaneously 
abolishes effector binding and modulates intrinsic and GEF-mediated nucleotide 
exchange reactions. Indeed, superposition of our predicted ligand-bound KRAS structure 
onto the HRAS:SOS complex (PDB 1NVV) suggests stabilization of the ternary complex 
(Figure 3.4). For example, side chains of H911 and Y912 of SOS are within a H-bonding 
distance from nitrogen atoms on the pyrazolopyrimidine ring of 11.  Additionally, as 
discussed the 1-piperazineethanol prevents CRaf binding by blocking the RBD from 
interacting with effectors residues of switch 1. Compound 11 and derivatives 12 and 13 
are the next step in targeting KRAS with small molecules. Compound 11 binds with 
nanomolar affinity and is effective at disrupting KRAS-effector interaction at low micro-
molar concentrations in in-vivo and biophysical experiments, a remarkable success for 
an initial screening effort.  A second compound, M1 may be a good starting point for 
further optimization since it has a strong effect on p-AKT levels during long incubation at 
very low micromolar concentrations. Additionally, our RICS data indicates this compound 
enhances KRAS dimerization, and we see enhanced nucleotide exchange in biophysical 
assays.  Together, these observations bring about the possibility of a new experimental 
tool. Finally, these results also provided a strong support for the reliability of the predicted 
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ligand-KRAS complex structures, and offered a viable route for additional modifications 
in future optimization efforts. 
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Figure 5.3: M1 docked on to SOS with 2PZ in a pocket near KRAS binding domain. (A) The 
structure of M1 and 2PZ, they share a similar core indole group. (B) Compound M1 (tan) and 
2PZ (blue) bound to SOS in a pocket near the KRAS catalytic interaction site. Compound M1 
forms a hydrogen bond (highlighted in yellow) with Y884 (purple) of SOS, possibly stabilizing it 
in a 𝜋-stacking interaction with R73 (green) of KRAS.   
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Figure 5.4: Compound M3 docked to KRASG12D Surface representation of KRASG12D (tan) and 
compound M3 (blue).  The caboxamide group attached to the central indazole rests between 
S39 and E37 although it does not fill up the space nor does it form any high affinity interactions 
with either residue.  The ethylamino forms a hydrogen bond with E37 but the piperdine-benzene 
group wraps around E37 rather than occupy the gap between E37 and M67.  The solvent 
exposed benzene is an unfavorable interaction that would reduce binding affinity.   
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5.2 Future directions 
 Compound 13 should be thoroughly evaluated in cell-based assays.  Preliminary 
testing indicated a decrease of p-ERK levels occurred at 1 μM treatment of BHK cells 
expressing GFP-KRASG12D after 3 hr in serum free media. Although more soluble then 
compound 11 we used 10 μM of 13 to disrupt GFP-KRASG12D binding in pulldown assays.  
Therefore, in signaling experiments the concentration range should be from 1 to 20 μM 
to determine if the compound can cause more than the ~50% reduction typically 
observed. Along with 2D cell proliferation assays with 13, compound 11 and 13 should 
be testing in 3D cell proliferation assays.  I would start with SKLU-1 and H1975 cells as 
a first test, since we saw the greatest difference in IC50 in compound 11 experiments. 
Finally, compound 11 and 13 should be used for similarity searches and new molecules 
based on these could be screened and tested.  
 It was demonstrated with NMR that compound M1 does bind to KRASWT probably 
at the p1 site and western blots indicate it decreased p-AKT after long incubation.  This 
indicates M1 should be explored further, although it needs to be resynthesized. The next 
steps would be gathering additional signaling data from long incubation experiments.  To 
assess whether M1 disrupts PI3K binding to KRAS, pulldown experiments with p110α, 
the subunit of PI3K, should be performed. Finally, the molecule could be optimized by 
removing the terminal benzene and rationally designing a functional group to interact 
with the residues that form the trench between E37 and M67.  
Molecule M3 was initially promising and has some features that make it attractive.  
Removing the terminal benzene would probably improve its binding.  Further the 
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carboxamide group could be lengthened with a short carbon-chain and this might allow 
it to hydrogen bond with S39 or G37 and improve its activity.  Additionally, the methyl 
groups on the amine could be removed to improve solubility and add hydrogen bond 
potential.  Finally, it could be used as the basis for a similarity search to generate a new 
group of potential binders to be screened in a small high throughput virtual screen and 
then a small cell-based screen.   
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